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I 
SUMMARY 
The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing each year. 
Although early stages of cSCC can still be treated successfully, late stage tumors invade 
into the surrounding tissue and metastasize to distant body sites, which is associated with 
a poor prognosis. Strong upregulation of the transmembrane glycoprotein Podoplanin 
(PDPN) has been demonstrated in various tumor entities including cSCC. Enhanced 
PDPN expression was correlated to poor cSCC patients’ outcome, but its function in skin 
cancer progression is still unknown. Therefore, my study aimed to define the impact of 
PDPN on cSCC carcinogenesis. The descriptive analysis of differentiated cSCC patients’ 
material showed PDPN overexpression in tumor cells and increased expression in 
activated fibroblasts, particularly at the invasive front of the tumor. To functionally examine 
the importance of PDPN in cSCC tumor cells, PDPN was deleted in human and murine 
cSCC cell lines by the CRISPR/Cas9 technology followed by functional in vitro assays. 
Human and murine cells harboring a PDPN knockout (KO) genotype showed similar 
morphology and proliferative behavior as control cells in monolayer culture system. 
Performing both the Boyden Chamber assay and the most advanced three-dimensional 
organoid skin cancer model demonstrated that the loss of PDPN in human cells neither 
affected transmigration nor invasion. Strikingly, murine Pdpn KO cells transmigrated and 
invaded with less efficiency in both approaches. The invasive phenotype of murine tumor 
cells was further characterized to be independent of epithelial-mesenchymal transition 
(EMT). An initial examination of one previously described PDPN downstream pathway 
revealed that ezrin recruitment and cytoskeletal remodeling were not impaired upon Pdpn 
KO in 2D culture. Complementing these in vitro approaches, labeled murine control and 
Pdpn KO cells were injected orthotopically into the dermis of nude mice, to define the role 
of PDPN in tumor progression in vivo. Formed tumors derived from control and Pdpn KO 
cells displayed a well-differentiated morphology with a PDPN-positive reaction in 
fibroblasts in the tumor stroma recapitulating human cSCC. Smaller tumors as well as 
delayed tumor outgrowth were observed upon Pdpn loss, which was due to reduced tumor 
cell proliferation in vivo. Moreover, abrogation of Pdpn resulted in diminished EMT-
independent tumor cell invasion. In conclusion, this study underscores the crucial impact 
of PDPN in cSCC progression. Future studies are required in order to characterize 
underlying molecular mechanisms that could propose potential therapeutic strategies 
targeting PDPN-dependent tumor cell invasion especially in late-stage cSCC patients. 
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ZUSAMMENFASSUNG 
Die Inzidenz des kutanen Plattenepithelkarzinoms (cSCC) nimmt jährlich zu. Obwohl frühe 
Stadien des cSCCs noch erfolgreich behandelt werden können, wachsen fortgeschrittene 
Tumore invasiv in das umliegende Gewebe ein und metastasieren zu entfernten Organen, 
was mit einer schlechten Prognose verbunden ist. Eine starke Hochregulierung des 
transmembranen Glykoproteins Podoplanin (PDPN) wurde in verschiedenen Krebsarten, 
einschließlich cSCC, gezeigt. Die erhöhte PDPN Expression korreliert mit einem 
schlechten Krankheitsausgang für cSCC Patienten. Allerdings ist seine Funktion in der 
cSCC Entwicklung noch immer unbekannt. Deshalb zielte meine Studie darauf ab, den 
Einfluss von PDPN in der cSCC Karzinogenese zu bestimmen. Die deskriptive Analyse 
von differenziertem cSCC Patientenmaterial zeigte eine PDPN Überexpression in 
Tumorzellen und in aktivierten Fibroblasten, insbesondere an der invasiven Tumorfront. 
Um die Bedeutung von PDPN in cSCC Krebszellen zu untersuchen, wurde PDPN mithilfe 
der CRISPR/Cas9-Technologie in humanen und murinen cSCC Zelllinien deletiert und 
anschließend diese Zellen in vitro funktionell analysiert. Humane und murine Zellen, die 
einen PDPN knockout (KO) Genotyp tragen, zeigten eine ähnliche Morphologie sowie ein 
ähnliches Wachstumsverhalten wie die Kontrollzellen im Einzelzellschicht-Kultursystem. 
Die Durchführung des Boyden-Kammer-Experiments und des drei-dimensionalen 
organoiden Hautkrebsmodells zeigten, dass der Verlust von PDPN in humanen Zellen 
weder die Transmigration noch die Invasion beeinträchtigte. Murine Pdpn KO Zellen 
hingegen transmigrierten und wuchsen weniger invasiv in beiden Ansätzen. Der invasive 
Phänotyp der murinen Tumorzellen war unabhängig von einer epithelial-mesenchymalen 
Transition (EMT). Eine erste Untersuchung einer bereits beschriebenen PDPN-
nachfolgenden Signaltransduktion zeigte, dass die Rekrutierung von Ezrin und die 
Modulation des Zytoskeletts nicht durch den Pdpn KO in der 2D Kultur beeinflusst waren. 
Zur Vervollständigung dieser in vitro Experimente, wurden markierte murine Kontroll- und 
Pdpn KO-Zellen orthotop in die Dermis von Nacktmäusen injiziert, um die Rolle von PDPN 
in der Tumorentwicklung in vivo zu definieren. Gewachsene Tumore, die von Kontroll- oder 
Pdpn KO-Zellen stammten, wiesen eine gut differenzierte Morphologie auf; darüber hinaus 
zeigten Fibroblasten im Tumorstroma eine PDPN-positive Reaktion, was insgesamt 
humane cSCCs rekapituliert. Durch den Verlust von Pdpn traten kleinere Tumore sowie 
verzögertes Tumorwachstum auf. Beide Beobachtungen waren auf ein vermindertes 
Krebszellwachstum in vivo zurückzuführen. Des Weiteren führte das Fehlen von Pdpn zu 
einer verringerter EMT-unabhängigen Tumorzellinvasion. Zusammenfassend 
unterstreicht diese Studie die entscheidende Bedeutung von PDPN in der cSCC 
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Entwicklung. Zukünftige Untersuchungen sind erforderlich, um die zugrunde liegenden 
molekularen Mechanismen zu charakterisieren und um mögliche therapeutische 
Strategien zu empfehlen, die auf die PDPN-abhängige Krebszellinvasion insbesondere in 
Patienten mit späten cSCC Stadien zielen. 
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1 INTRODUCTION 
1.1 Physiology and Pathology of the Skin 
1.1.1 The Structure of the Skin 
The skin is the largest organ of the human body and comprises several layers (Watt 2014). 
Starting from outside, these layers are composed of the epidermis including several 
appendages like hair roots, sebaceous and sweat glands. Below the epidermis is the 
dermis as the underlying connective tissue consisting mostly of fibroblasts and 
extracellular matrix (ECM). The deepest layer is the dermal white adipose tissue (DWAT; 
Figure 1).  
 
 
Figure 1 The human skin architecture.  
The skin is composed of multiple layers. The outermost layer is the stratified epithelium with 
several appendages like sebaceous and sweat glands as well as hair follicles. The epidermis is 
separated from the subjacent dermis by the BM. The dermis consists of ECM produced by 
fibroblasts and harbors touch receptors and blood as well as lymphatic vessels. The lowest 
layer is the DWAT. Terminal differentiation of epidermal keratinocytes results in a barrier layer 
protecting the body from different kind of traumas (e.g. bacterial infection, UV radiation, loss of 
fluid). Adapted from MacNeil (2007). 
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The epidermis is separated from the underlying dermis by the basement membrane (BM) 
which is a thin layer of ECM components like type IV collagen and laminin secreted by 
keratinocytes and fibroblasts (Fuchs and Raghavan 2002, Simpson et al. 2011, Watt 
2014). The skin forms a barrier protecting the body from the environment against physical 
(e.g. mechanical stress or ultraviolet (UV) radiation), chemical (e.g. irritants) or microbial 
(e.g. bacteria or viruses) traumas (Fuchs and Raghavan 2002, Simpson et al. 2011). 
Moreover, the skin also prevents dehydration of the body by retaining body fluids and is 
involved in thermoregulation (Fuchs and Raghavan 2002, Simpson et al. 2011, Watt 
2014). 
 
1.1.1.1 The Epidermis 
The epidermis is composed of multilayered keratinocytes which are the most abundant 
cell type of this skin layer (MacNeil 2007). Additional epidermal cells are melanocytes, 
Langerhans and Merkel cells (MacNeil 2007). Keratinocytes which are positioned in the 
innermost layer are named basal keratinocytes and are anchored to the BM (Alonso and 
Fuchs 2003, Watt and Fujiwara 2011). Keratinocytes located in this so-called basal layer 
(stratum basale) are able to proliferate asymmetrically, referred as transiently amplifying 
cells, thus, resulting in keratinocytes which on the one side stay at the BM and on the other 
side upon a trigger leave the basal layer to undergo a process of terminal differentiation 
(Fuchs and Raghavan 2002, Alonso and Fuchs 2003). During this process which is also 
named keratinization or stratification, keratinocytes go through specific morphological 
changes until they reach the surface of the skin. Thereby, the different epidermal layers 
can be identified: the basal layer, the spinous layer (stratum spinosum), the granular layer 
(stratum granulosum) and the cornified layer (stratum corneum; Figure 2, Simpson et al. 
(2011)). The skin is a constantly renewing tissue as cells in the cornified layer are 
continuously replaced by newly differentiated cells (Boukamp 2005b). 
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Figure 2 Schematic illustration of the epidermis.  
The epidermis is made up of several distinct layers: basal (stratum basale), spinous (stratum 
spinosum), granular (stratum granulosum) and cornified layer (stratum corneum). Keratinocytes 
in the basal layer, so-called basal cells, are anchored to the BM which divides the epidermis 
and underlying dermis from each other. The ECM in the dermis is produced by fibroblasts. Basal 
cells can enter the process of terminal differentiation undergoing specific morphological 
changes until corneocytes in the top layer are shed. Alonso and Fuchs (2003). 
 
Basal keratinocytes express specific keratin (K) filaments K5 and K14 and are connected 
to the BM through hemidesmosomes and integrin-based adhesion molecules (Candi et al. 
2005, Simpson et al. 2011). After leaving the basal layer, cells maintain their metabolic 
activity while the keratin expression profile is changed (Fuchs 2008). Suprabasal cells stop 
the expression of K5 and K14 and start expressing K1 and K10 (Fuchs and Green 1980, 
Candi et al. 2005). Spinous keratinocytes start to strengthen their cell-cell junctions, the 
so-called desmosomes, by enhancing the intermediate filament network (Alonso and 
Fuchs 2003). Granular cells generate lipid-rich granules and produce filaggrin which links 
keratin filaments into tight bundles (Candi et al. 2005, Fuchs 2008). Moreover, suprabasal 
keratinocytes activate several transglutaminases that are important to interconnect 
structural filaments like filaggrin, loricrin and involucrin to build the cornified envelope 
(Candi et al. 2005). The aggregation of these structural proteins leads to the flattening of 
the keratinocytes resulting in squames within the cornified layer, which are dead-cell 
enucleated remnants (Candi et al. 2005). This outermost layer comprised of corneocytes 
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creates a mechanical barrier for the skin which is shed off by proteolytic cleavage of the 
cornified envelope, the so-called desquamation (Candi et al. 2005, Watt 2014).  
 
1.1.1.2 The Dermis 
The main cell type within the dermis is the fibroblast (Watt 2014, Watt and Fujiwara 2011). 
Other cellular components are immune cells, blood and lymphatic vessels as well as 
nerves and the arrector pili muscle (Watt and Fujiwara 2011). Like in the epidermis, the 
dermis can be dissected into multiple layers: (i) the papillary dermis, which is directly below 
the BM and contains the highest density of fibroblasts; (ii) the reticular dermis, which is 
dense of collagen fibers; (iii) the hypodermis or DWAT, which mainly consists of white 
adipocytes (Watt 2014, Watt and Fujiwara 2011). Fibroblasts are responsible for the 
secretion of ECM components as well as nutrient supply of the avascular epidermis (Watt 
and Fujiwara 2011). Cellular debris within the skin is cleared by skin-resident 
macrophages (Davies et al. 2013). 
 
1.1.2 Cutaneous Squamous Cell Carcinoma 
As the outermost layer protecting the body from various environmental stress, the skin is 
prone for cancer development which can originate from various cell types of the multiple 
cutaneous layers. The most aggressive skin cancer is the malignant melanoma originating 
from epidermal and dermal melanocytes (reviewed in Bastian (2014)). However, the most 
frequent cancer worldwide in the Caucasian population are the non-melanoma skin 
cancers (NMSC; Leiter et al. (2017), Waldman and Schmults (2019)). NMSC is 
subclassified as basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma 
(cSCC) as well as other tumor entities including Merkel cell carcinoma and fibrosarcoma 
(reviewed in Boukamp (2005b), Augsburger et al. (2017), Waldman and Schmults (2019)). 
The majority of NMSC are the keratinocyte-derived tumors BCC which accounts for around 
80 % and cSCC with roughly 20 % of all skin cancers (Leiter et al. 2017, Nagarajan et al. 
2018, Waldman and Schmults 2019).  
The incidence of cSCC was ranged from 15 to 35 per 100,000 people in the United States 
of America (Burton et al. 2016). However, the accurate numbers are difficult to determine 
and often underestimated as many cancers are not registered or only the first tumor is 
recorded (Leiter et al. 2017). The incidence is increasing each year with an expected rate 
of 2-4 % due to the aging population, environmental impacts as a result to certain lifestyle 
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behavior (e.g. sunbathing) and higher detections rates due to more frequent screenings 
(Alam and Ratner 2001, Burton et al. 2016, Leiter et al. 2017). In comparison to BCC, 
which grows locally invasive but hardly metastasizes, the metastatic risk of cSCC is only 
5 % but can reach 50 % in defined clinical settings associated with poor long-term survival 
(Alam and Ratner 2001, Boukamp 2005b, Huang and Balmain 2014).  
The development of cSCC is a multistep process with distinct stages (Figure 3, Boukamp 
(2005b), Ackerman and Mones (2006)). Originating from epidermal keratinocytes, actinic 
keratosis (AK) is associated with hyperplasia and considered to be a precursor lesion 
(Ackerman and Mones 2006, Fernandez Figueras 2017). It can persist at the same stage 
for many years but left untreated, it may progress to cSCC in situ (CIS) with increased 
genetic instability (Ackerman and Mones 2006, Ratushny et al. 2012, Fernandez Figueras 
2017). The differentiation program is partially disrupted in AK, whereas it progresses to a 
complete malfunction becoming a CIS (Ratushny et al. 2012). Additional mutations in 
oncogenes result finally in an invasively growing or even metastatic cSCC (Ratushny et 
al. 2012).  
 
 
Figure 3 Schematic representation of cSCC development. 
cSCC carcinogenesis is a multistep process. UV radiation causes DNA alteration in epidermal 
keratinocytes. If these mutated cells do not undergo apoptosis, they start to grow uncontrolled 
resulting in AK. Left untreated, AK can progress to a CIS and to invasively growing cSCC which 
breaks through the BM. During this multistage carcinogenesis genetic instability is increasing as 
well as additional oncogenes are mutated. Adapted and modified from Alam and Ratner (2001). 
 
The initiation and progression of cSCC are primarily due to sunlight exposure mediated by 
UV radiation (Boukamp 2005b, Huang and Balmain 2014, Leiter et al. 2017). Other factors 
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such as older age, fair skin, exposure to chemicals (e.g. arsenic) and immunosuppression 
are also associated with cSCC development (Leiter et al. 2017, Nagarajan et al. 2018, 
Waldman and Schmults 2019). Exposure to UV light causes DNA alterations in multiple 
genes. The most frequent aberration, which appears early in cSCC development, is the 
mutation in the TRP53 tumor suppressor gene in around 50 % of the cases (Popp et al. 
2002, Boukamp 2005a). The typical UVB signature mutation is manifested as C to T 
transition at CC sites (Lomas et al. 2012, Nagarajan et al. 2018). In around 20 %, the rat 
sarcoma (RAS) proto-oncogene is mutational locked in its activated state (Boukamp 
2005a). In particular, UV-sensitive CC sites are preferentially affected within the Harvey 
(Ha)-RAS gene in comparison to Kirsten- and N-RAS. Failure to repair these DNA 
mutations normally results in keratinocyte apoptosis; however, some cells survive 
generating e.g. mutated p53 patches leading to an abnormal cell population and may be 
the beginning of an AK which then can further progress to cSCC (Alam and Ratner 2001, 
Boukamp 2005b).  
cSCC is clinically presented as red scaly plaque and typically on sun-exposed areas in 
older-aged individuals (Popp et al. 2002, Ackerman and Mones 2006, Waldman and 
Schmults 2019). The histopathological examination ranges from well to poorly 
differentiated morphology (Waldman and Schmults 2019). Depending on the stage and 
location, different therapeutic strategies are pursued. Well-defined small tumors can be 
treated by non-surgical destructive options for instance cryosurgery and curettage (Alam 
and Ratner 2001, Jennings and Schmults 2010, Nagarajan et al. 2018). These techniques 
are inexpensive and easy to perform. Nevertheless, the primary treatment option is 
surgical removal leading to lowered recurrence and metastasis rates despite higher costs 
(Alam and Ratner 2001). Standard surgical excision is performed for low-risk and 
micrographic surgery for high-risk cSCC or tumors at cosmetically sensitive areas 
(Jennings and Schmults 2010, Nagarajan et al. 2018, Waldman and Schmults 2019). 
Moreover, the disease risk is highly linked to immunosuppression, thus, newer therapy 
options like checkpoint inhibition are currently under review. Migden and colleagues 
treated patients with locally advanced and metastatic cSCC with Cemiplimab, an antibody 
directed against programmed death 1 (PD-1), showing that approximately half of the 
patients responded to this monoclonal antibody therapy (Migden et al. 2018). Even though 
the majority of cSCC has an excellent prognosis, the survival rate of metastatic or 
unresectable tumors drops to 20 % (Alam and Ratner 2001). These late-stage tumors can 
be treated with radiation and/or chemotherapy as palliative care or additional possibility 
prior to surgery (Jennings and Schmults 2010, Waldman and Schmults 2019).  
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1.2 In Vitro Systems to Investigate Cutaneous Squamous Cell 
Carcinoma Tumorigenesis 
In order to gain better insights into the development of cSCC, different model systems 
ranging from monolayer cell culture via three-dimensional (3D) organotypic systems to 
animal models have been established.  
 
1.2.1 Cell Lines 
Monolayer cultures represent the simplest system to reveal underlying molecular 
mechanisms by performing functional tests. For in vitro as well as in vivo analysis of 
epithelial skin tumors, several cell lines representing different tumor stages have been 
established. Based on their diverse genetic alterations (Table 1), these cell lines are used 
to investigate different functional aspects of cSCC.  
The MET cell lines represent a sequential series of poorly differentiated cSCCs as all lines 
were derived from a single immunosuppressed renal transplant patient (Popp et al. 2000, 
Proby et al. 2000): MET-1 cells were isolated from a primary cSCC which developed on 
the back of the left hand; MET-2 and -3 from two recurrences at the same site as the 
primary tumor; and MET-4 cells from an axillary lymph node metastasis. The SCL-I and 
the SCL-II cell lines were established from two patients suffering facial cSCCs derived 
from an untreated differentiated and a locally radiated undifferentiated cSCC, respectively 
(Tilgen et al. 1983). SCC-12 and SCC-13 cells were isolated from cSCCs of the facial 
epidermis from two different patients who received immunosuppressive drugs upon kidney 
transplantation or radiation therapy, respectively (Rheinwald and Beckett 1981). Both 
tumors presented a well-organized differentiated histology.  
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Table 1 Overview of established cell lines and their genetic alterations and histology.  
Murine cell line is indicated by *. 
Cell line Origin Genetic alterations, 
histology 
Reference 
MET-1 primary cSCC, hand p53 WT, poorly differentiated Popp et al. (2000), 
Proby et al. (2000) 
MET-2 recurrence of 
primary cSCC, hand 
p53 WT, poorly differentiated Popp et al. (2000), 
Proby et al. (2000)  
MET-3 recurrence of 
primary cSCC, hand 
p53 WT, poorly differentiated Popp et al. (2000), 
Proby et al. (2000) 
MET-4 cSCC metastasis, 
lymph node 
p53 WT, poorly differentiated Popp et al. (2000), 
Proby et al. (2000) 
SCL-I primary cSCC, face p53 mutant, differentiated Tilgen et al. (1983) 
SCL-II primary cSCC, face p53 mutant, poorly 
differentiated 
Tilgen et al. (1983) 
SCC-12 primary cSCC, face p53 mutant, differentiated Rheinwald and  
Beckett (1981) 
SCC-13 primary cSCC, face p53 mutant, differentiated Rheinwald and  
Beckett (1981) 
HaCaT keratinocyte cell line p53 mutant, non-tumorigenic Boukamp et al. (1988) 
HaCaT A5 oncogenic Ha-RAS 
keratinocyte cell line 
benign growth in vivo, 
differentiated 
Boukamp et al. (1990) 
HaCaT II-4 oncogenic Ha-RAS 
keratinocyte cell line 
invasive growth in vivo, 
differentiated 
Boukamp et al. (1990) 
BDVII* DMBA-induced 
cSCC 
Ha-Ras mutant, differentiated Fusenig et al. (1978) 
 
To establish a human keratinocyte cell culture, cells of a not extensively sun-exposed area 
were isolated from a melanoma patient (Boukamp et al. 1988). This keratinocyte cell line 
was generated under specific culture conditions designating “human adult low calcium 
high temperature keratinocytes” (HaCaT). During the process of establishing this cell line, 
HaCaT cells spontaneously immortalized in vitro, while they still maintained their highly 
differentiated morphology (Boukamp et al. 1988, Micallef et al. 2009). Originated from 
these HaCaT cells, additional cell lines were established via transfecting the mutant Ha-
Ras gene (Boukamp et al. 1990). Hence, several clones were generated which were able 
to form benign or malignant tumors in vivo. For instance, HaCaT A5 was slowly growing 
with highly differentiated benign tumors, whereas injection of HaCaT II-4 cells resulted in 
highly differentiated but locally invasive cSCCs. Thus, HaCaT cells represent another 
model system which can be used for the analysis of the multistep skin cancer 
development.  
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Besides several human cell lines, only one murine cSCC line was established, namely 
BDVII. This cell line was generated by chemical induction of cSCC in C57BL/6 mice 
allowing syngeneic injection into this mouse strain (Fusenig et al. 1978). Employing graft 
models in the backskin of mice which comprise of tumor cell suspension alone or tumor 
cell cultures on top of a collagen matrix, BDVII cells grew invasively into the host tissue 
and formed stratified structures (Fusenig et al. 1978). Furthermore, subcutaneous (s.c.) 
inoculation into mice verified invasively growing tumors with differentiated cornified tissue 
(Lederle et al. 2010, Meides et al. 2014). Thus, this murine cSCC cell line offers a great 
model system to investigate skin cancer development in immunocompetent C57BL/6 mice.  
1.2.2 Three-Dimensional Skin Models 
For the functional analysis examining keratinocytes or cutaneous tumor cell characteristics 
such as migration and invasion, different 3D in vitro model systems have been established. 
In comparison, monolayer-based cultures lack physiological context as superior properties 
of 3D culture conditions are the addition of fibroblasts as feeder layer which can be 
embedded in a certain type of matrix. This scaffold enables keratinocytes or skin tumor 
cells to grow on top of the dermal equivalent recapitulating skin or tumor features, 
respectively.  
In the traditional 3D system composed of epithelial cells (either keratinocytes or tumor 
cells) and murine fibroblasts or collagen-embedded human fibroblasts (e.g. hydrogel-
based model), ECM lacks mechanical stability resulting in contraction of the culture 
(Muffler et al. 2008, Wolf et al. 2009). Thus, this results in limiting cultivation time (only up 
to 3-4 weeks). Moreover, ECM composition in hydrogel-based models is insufficiently 
reflected (Wolf et al. 2009). However, these characteristics play a decisive role to 
investigate migration and invasion of cSCC tumor cells. Hence, the 3D organotypic skin 
cancer model (SCM) established by Berning and colleagues represents the most 
advanced system (Figure 4; Berning et al. (2015)). In this model system primary human 
dermal fibroblasts (hDFs) serve as a feeder layer and produce ECM components 
themselves over four weeks of cultivation. This fibroblast-derived matrix (fdm) reflects the 
ECM composition and geometry of human papillary dermis. Human cSCC tumor cells 
cultivated on top of this dermal compartment form a well-established multilayered 
epithelium. All in all, the SCM system closely mimics the epidermal-dermal environment in 
vitro as tumor cells grow air-exposed on top of a thick fibroblast feeder layer allowing 
invasive growth of tumor cells (Berning et al. 2015). 
 
INTRODUCTION 
 
 
12 
 
Figure 4 The three-dimensional in vitro skin and skin cancer model.  
Scheme and timeline of the SCM according to Berning et al. (2015). hDFs are provided by three 
seeding steps and cultured for four weeks to generate fdm. cSCC cells are seeded on top of the 
dermal equivalent and cultured air-exposed resulting in a multilayered epidermal compartment. 
Cultures can be harvested at different time points allowing histological and 
immunohistochemical analyses. 
 
1.3 Mouse Models to Study Cutaneous Squamous Cell 
Carcinoma 
The mouse is the preferred model as this complex system can be used to mimic human 
pathologies incorporating all factors of a living organism such as tumor growth, 
interaction of tumor with stromal cells, immune response and tumor angiogenesis. 
Different model systems are utilized to examine the multistep process of cSCC 
development in vivo. Importantly, it has to be kept in mind that the murine skin is 
structured differently in several aspects from the human skin. The epidermal layers as well 
as the dermis in mice are much thinner than in humans and moreover, the murine skin has 
a much higher density of hair follicles (Watt and Fujiwara 2011). So it is contentious 
whether obtained results can be transferred in regard to the human situation. However, 
the mouse represents still the best model to recapitulate tumor growth and 
characteristics in a mammalian organism. 
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1.3.1 UV Radiation 
cSCC develops at sun-exposed body sites which can be explained by chronic UV damage. 
Therefore, it is self-explaining to use UV light to induce cSCC in mice. Several groups used 
immunocompetent hairless mice (e.g. SKH-1) which lack the expression of the Hairless 
gene. These studies showed that UV exposure resulted in typical human cancer 
characteristic for instance, frequent Trp53 mutation and only a low mutation rate in the Ha-
Ras oncogene (reviewed in van Kranen et al. (1995), van Kranen and de Gruijl (1999)). 
Nevertheless, it was already demonstrated that the Hairless gene plays a role in skin 
metabolism which might influence skin cancer development (Kumpf et al. 2012). 
 
1.3.2 Chemically Induced Skin Tumors 
The malignant transition of human epidermal cells in cSCC was found to be a multistep 
process, in which numerous genetic and epigenetic events result in the transformation of 
normal to malignant cellular stages. Several mouse models based on chemical cancer 
induction have been established (reviewed in Abel et al. (2009)). One of the best-
established mouse skin carcinogenesis models applying 7,12-Dimethylbenz-[a]-
anthracene (DMBA) and the most active constituent of croton oil 12-O-
tetradecanoylphorbol-13-acetate (TPA) has been an important tool to investigate epithelial 
hyperplasia and multistep processes of tumor development and progression (Berenblum 
and Shubik 1947, Boutwell 1964). 
In this model system, tumor formation is chemically induced in the backskin of mice upon 
a single subcarcinogenic dose of DMBA resulting in point mutations including nucleotide 
exchanges in the proto-oncogene Ha-Ras (initiation; Kemp (2005), Schwarz et al. (2013)). 
Upon initiation, the skin is continuously treated several times a week with the tumor 
promoting agent TPA (Boutwell 1964). In this second step, the so-called promotion, TPA 
causes an inflammatory reaction which is associated with epidermal hyperplasia (Stanley 
et al. 1991). Due to induced cell proliferation, Ha-Ras mutated keratinocytes expand 
clonally leading to the generation of benign tumor, so-called papilloma (PAP; (Finch et al. 
1996). TPA treatment is stopped after 20 weeks and consequently, the majority of PAP 
regresses. However, some PAP progress further in the observation period (up to 52 
weeks) resulting in invasively growing cSCC (Kemp 2005, Abel et al. 2009, Schwarz et al. 
2013). This model system recapitulates human cSCC carcinogenesis as tumors develop 
in multiple steps and the morphology is similar to human tumors (Benjamin and 
Ananthaswamy 2007, Abel et al. 2009). However, there are also some limitations of this 
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mouse model. Treated mice primarily develop PAP which does not represent human 
equivalent as human PAP form rather due to human papilloma virus infections (Schwarz 
et al. 2013). In human tumor initiation the Trp53 gene is the main target of chronic UV 
damage, but in this model, Ha-Ras is primarily targeted by topical DMBA treatment 
(Benjamin and Ananthaswamy 2007). Furthermore, the conversion from benign PAP to 
invasively growing cSCC strongly depends on the chemical dosage and background of the 
used mouse strain (Reiners and Singh 1997, Yamakage et al. 2000, Gebhardt et al. 2008, 
Abel et al. 2009).  
 
1.3.3 Genetic Engineered Mouse Models 
A variety of genetic engineered mouse models (GEMMs) has been established including 
global or skin-specific inactivation of tumor suppressor or activation of oncogenes 
(reviewed in Eferl and Casanova (2015)).  
Mice with a deficiency of the tumor suppressor gene p53 do not develop skin tumors 
spontaneously (Harvey et al. 1993). Additional application of the chemical skin 
carcinogenesis protocol by topical DMBA/TPA treatment allowed addressing the question 
of p53 contribution in skin tumorigenesis. This example demonstrates that if the gene of 
interest is not a driver mutation, additional tumor initiating and/or promoting is required 
(e.g. DMBA/TPA-induction; Kemp (2005)). Employing this model, Kemp and colleagues 
were able to show that the malignant progression from PAP to cSCC depends on this 
tumor suppressor as PAP progressed more rapidly to cSCCs.  
In the K5-hSOS-F mouse model the human Ras activator Son of Sevenless (hSOS-F) is 
activated under the basal cell-specific promoter K5 (Sibilia et al. 2000). These transgenic 
mice showed an increased epidermal proliferation and develop PAP within weeks. These 
PAPs grew so quickly, that mice needed to be sacrificed before malignant transformation 
of arisen PAP could be investigated. 
These two examples show that GEMMs are a powerful tool to study skin diseases as well 
as tumorigenesis and to test the ability of specific genes in tumor initiation and progression. 
GEMMs develop de novo tumors over a longer time period compared to injection models 
(Kersten et al. 2017). Nevertheless, this is the preferred model system closely 
recapitulating human tumor characteristics also due to more realistic slow tumor 
development.  
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1.3.3 Orthotopic Tumor Cell Injection 
Besides inducing skin carcinogenesis by exogenous factors like chemicals or UV radiation, 
or by altered gene expression, tumor cells can also be injected orthotopically. Two different 
inoculation sites are commonly used: (i) while injecting tumor cells s.c., the tumor develops 
below the skin and (ii) performing intradermal (i.d.) injections, tumor cells grow within the 
dermis. Depending on the cell line and cell number either injection site results in fast-
growing tumors within weeks. While s.c. administration is rather easy to perform, i.d. 
injection requires some experience to administer cells just under the superficial layer of 
the epidermis. However, depending on the scientific question which is addressed, it is 
important to keep in mind that the microenvironment differs on the injection site. Within the 
dermis, tumor cells get into closer contact with fibroblast and other stromal cells than 
cancer cells which have been injected s.c. (Bonnotte et al. 2003). Thus, i.d. inoculation 
represents the more conclusive model to address the relation of tumor and stromal cell 
during epidermal tumor cell invasion.  
 
The underlying genetic program in cSCC development and progression is only partly 
understood. Thus, the described in vitro and in vivo model systems are still used to clarify 
important signaling pathways and involved genes. One candidate which has been 
associated with poor long-term survival especially in late-stage cSCC patients is the 
transmembrane protein podoplanin (PDPN; Vinicius de et al. (2011). Further information 
on this protein as well as data indicating its role in cSCC progression is presented in the 
following chapter.  
 
1.4 The Glycosylated Transmembrane Protein Podoplanin 
1.4.1 Podoplanin Function in Physiology 
The mucin-like glycoprotein PDPN was named due to its function in flattening podocytes 
in the kidney (Breiteneder-Geleff et al. 1999). The protein was independently described in 
different biological contexts and therefore, it is also known by several designations. The 
clone OTS-8 was isolated from mouse lung tissue treated with TPA (Nose et al. 1990). 
Farr and colleagues found a glycoprotein 38 in mouse peripheral lymphoid tissue (Farr et 
al. 1992). The rat homolog T1α was described in rat type I lung alveolar cells (Rishi et al. 
1995). Furthermore, E11 was reported to be expressed in osteoblasts, lung and lymphatic 
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endothelial cells (LECs; Wetterwald et al. (1996)). PDPN expression in LECs is commonly 
used as a valid marker for lymphatic vessels (Breiteneder-Geleff et al. 1999). Furthermore, 
PA2.26 was reported in mouse skin keratinocytes upon wound healing and chemical 
carcinogenesis (Gandarillas et al. 1997). Aggrus/gp44 was identified as a platelet-
aggregation factor (Kato et al. 2003).  
Although PDPN is expressed in a variety of different tissues, the physiological function is 
mostly unknown. Several studies using Pdpn knockout (KO) mice have demonstrated its 
crucial role in the development of different tissues. Type I alveolar cells lacking Pdpn have 
deregulated proliferation and differentiation resulting in impaired inflation of the lung and 
thus, in respiratory failure and perinatal death of these animals (Ramirez et al. 2003). 
Schacht and colleagues showed that the development of lymphatic endothelium is 
impaired upon Pdpn loss and these defects are leading to reduced lymphatic transport 
and hence, to lymphedema (Schacht et al. 2003). The lack of Pdpn in the heart results in 
dysregulation of epithelial-mesenchymal transition (EMT) and thus, to hypoplasia in Pdpn-
deficient animals (Gittenberger-de Groot et al. 2007, Douglas et al. 2009). Moreover, 
constitutive Pdpn ablation induces hemorrhages in the embryonic brain (Lowe et al. 2015).  
Focusing on the skin, basal cells of sebaceous glands, hair follicles and lymphatic vessels 
express PDPN (Honma et al. 2012, Wojciechowska-Zdrojowy et al. 2016). However, it is 
expressed neither by basal keratinocytes of the interfollicular epidermis nor by dermal 
fibroblasts (Gandarillas et al. 1997, Honma et al. 2012). Employing an in vivo loss-of-
function (LOF) approach, keratinocytes lacking Pdpn resulted in normal mouse 
development and showed no signs of skin abnormalities (Baars et al. 2015). 
 
Despite performing these studies, the biological function remains unclear. Although PDPN 
lacks a catalytical domain, it mainly functions through protein-protein interactions.  
 
1.4.2 Podoplanin Protein Structure and Its Interaction Partners 
The type I transmembrane protein PDPN consists of 162 amino acids in humans and the 
murine homolog is 172 amino acids long (Martin-Villar et al. 2005). The protein-protein 
interactions are mediated by the different domains of PDPN including an ectodomain (ED), 
a single transmembrane (TM) domain and a short intracellular (IC) tail (Figure 5).  
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Figure 5 Schematic representation of PDPN and its interaction partners.  
The extracellular and intracellular domains of PDPN have been shown to interact with various 
proteins including CD44, CLEC-2, CCL21, CD9 and the ERM protein family. Adapted from 
Astarita et al. (2012). 
 
The ED is heavily O-glycosylated with sialic acid α-2,3 linked to galactose at serine (Ser) 
and threonine (Thr) residues (Scholl et al. 1999). Scholl and colleagues demonstrated that 
these sugar residues account mainly for the molecular weight of PDPN (Scholl et al. 1999). 
Moreover, they isolated protein extracts from different organs and revealed that it had a 
different molecular mass. These results as well as the data of the simultaneous PDPN 
discovery suggest that this glycoprotein is modified differently resulting in varying 
molecular weight ranging from 36 to 43 kDa (Gandarillas et al. 1997, Farr et al. 1992, Kato 
et al. 2003). Nevertheless, whether these modifications are organ- or even tumor-specific 
has not been explored yet. So far, Kato and Kaneko gave the only evidence by developing 
an antibody targeting cancer-specific PDPN (Kato and Kaneko 2014). Epitope mapping 
was performed using an enzyme-linked immunosorbent assay (ELISA). The established 
antibody detected only an aberrant glycosylated PDPN (Thr54 and probably Ser56) which 
was expressed by brain and oral SCC (OSCC) tumor cells and not in lymphatic vessels. 
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Whether this antibody represents a new possibility to treat patients with PDPN-positive 
tumors is still under observation. The glycosylation of PDPN is responsible for the main 
protein function. The importance of this posttranslational modification was shown in vivo 
when the glycosylation was abrogated. Mice lacking the T-synthase which is responsible 
for O-glycosylation suffered from the same phenotypic defects similar to global Pdpn KO 
mice (Ju and Cummings 2002, Fu et al. 2008). Three tandemly repeated motifs 
(EDXXXVTPG) in the ED were identified and named platelet aggregation-stimulating 
domains (PLAG1-3; (Kato et al. 2003, Sekiguchi et al. 2015). The glycosylation in these 
domains is essential for the interaction with the C-type lectin-like receptor 2 (CLEC-2; 
Suzuki-Inoue et al. (2007)). Kaneko and colleagues reported that the glycosylation of Thr 
at position 52 within the PLAG3 domain in human PDPN and Thr34 in the PLAG1 domain 
in the murine homolog is responsible for the interaction with CLEC-2 (Kaneko et al. 2007, 
Bianchi et al. 2014). CLEC-2 is expressed by platelets and immune cells resulting in 
platelet aggregation and increased motility of immune cells and is so far the only known 
receptor for PDPN (Astarita et al. 2012, Suzuki-Inoue et al. 2007). The CLEC-2-PDPN-
interaction is critical for the process of lymphatic vessel maintenance as platelet 
aggregation is induced by PDPN expressing LECs (Suzuki Inoue et al. 2010). Upon PDPN 
binding, CLEC-2 dimerizes and is phosphorylated in the IC domain by the kinase Syk 
(Suzuki-Inoue et al. 2007). Consequently, phospholipase C gamma 2 (PLCȖ2) is activated 
resulting in platelet aggregation (Navarro-Nunez et al. 2013). Moreover, Acton and 
colleagues described a functional role of CLEC-2 in dendritic cell (DC) motility (Acton et 
al. 2014). CLEC-2 is expressed by skin as well as lymph node DCs. Upon PDPN binding, 
CLEC-2 dimerizes and the downstream signaling via Syk and PLCȖ2 is activated as in 
platelets. The Vav protein gets activated additionally, reducing Ras homologe (Rho) A 
activity. Based on the abolished contractility of the actomyosin skeleton, the actin 
cytoskeleton is remodeled and DCs can spread along stromal scaffold, extend protrusions 
and migrate.  
The standard isoform of CD44 is expressed in various cell types in physiology and 
pathology and interacts with the carbohydrate moieties of the PDPN ED (Martin-Villar et 
al. 2010). Performing in vitro studies as well as using an experimental skin carcinogenesis 
model, they reported that both glycoproteins cooperate leading to enhanced cell migration 
and tumor progression. However, further investigations are required to unravel the exact 
interaction mechanism between these glycoproteins.  
The chemokine CCL21 is another partner interacting with PDPN. It was described that 
PDPN builds complexes with CCL21 on the basal cell membrane of LECs in a 
glycosylation-dependent manner (Kerjaschki et al. 2004). These complexes are shed into 
the perivascular stroma forming a CCL21 gradient for the attraction of CCR7-positive 
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immune cells resulting in the rejection of kidney transplants in humans. However, the 
underlying mechanism of PDPN shedding was not described. The proteolytic cleavage of 
potential sites within the ED is masked due to the posttranslational addition of glycans 
(Pan et al. 2014).  
Yurrita and colleagues reported that instead of degrading PDPN via cleavage of the ED, 
the TM domain is cleaved mediated by metalloproteases (Yurrita et al. 2014). Besides 
degradation, the homodimerization and localization of PDPN to the plasma membrane 
within lipid rafts rely on the GXXXG motif, which is highly conserved in all species (Russ 
and Engelman 2000, Fernandez-Munoz et al. 2011),  
Moreover, PDPN associates with CD9, a tetraspanin protein, via its TM (Nakazawa et al. 
2008). The interaction of PDPN with CD9 showed that exogenous expression of CD9 in 
PDPN-positive HT1080 fibrosarcoma cells resulted in decreased formation of pulmonary 
metastases in an experimental metastasis model (Nakazawa et al. 2008). Moreover, they 
reported that the reduction of metastasis formation is most likely due to decreased platelet 
aggregation. Although the PDPN-CLEC-2-interaction is not affected by CD9, CD9 
suppresses CLEC-2 multimerization and hence, decreased platelet aggregation.  
The nine amino acids short IC domain is required for PDPN activity as well as for the 
localization to the cell membrane (Fernandez-Munoz et al. 2011, Martin-Villar et al. 2015). 
Besides other proteins, PDPN recruits the members of the ezrin, radixin and moesin (ERM) 
protein family (Scholl et al. 1999, Martin-Villar et al. 2005). This recruitment can lead to 
EMT (Martin-Villar et al. 2006, Fernandez-Munoz et al. 2011). Moreover, the localization 
of PDPN to the plasma membrane is crucial for invadopodia functionality (Martin-Villar et 
al. 2015).  
Members of the ERM protein family consist of an N-terminal ERM associated domain (N-
ERMAD) and a C-terminal ERMAD (C-ERMAD) which are linked by flexible α-helices 
(Gary and Bretscher 1995). The N-ERMAD interacts with numerous proteins, whereas the 
C-ERMAD binds to F-actin, thus, building a regulated linkage between membrane proteins 
to the actin cytoskeleton (Bretscher et al. 2002). The N- and C-terminal domains are 
binding to each other with high affinity resulting in a closed conformation (Gary and 
Bretscher 1995). A two-step process is needed for ERM activation. First, ERM proteins 
are recruited to phosphatidyl-inositol 4,5-bisphosphate regions at the cell membrane 
(Fehon et al. 2010). Second, various kinases including Rho GTPases phosphorylate ERM 
proteins at Thr residues in the C-ERMAD (reviewed in Gary and Bretscher (1995), 
Bretscher et al. (2002)). In the context of PDPN, ERM proteins are binding to the cluster 
of three basic amino acids within the IC domain (human: RKMSGRYSP, mouse: 
KKISGRFSP (Scholl et al. 1999, Martin-Villar et al. 2006)). Hence, Rho GTPases are 
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locally increased and activated. Subsequently, Rho-associated kinase (ROCK) is 
stimulated leading to phosphorylation and stabilization of PDPN-attached ERM proteins. 
ERM proteins remodel the actin cytoskeleton linked to membrane-bound PDPN setting the 
cell for migration. In functional in vitro studies performing exogenous overexpression of 
PDPN in human immortalized keratinocytes, mouse carcinoma as well as breast cancer 
cell lines, it was shown mechanistically that single or collective cell migration and invasion 
were mediated by PDPN in an EMT-independent and -dependent manner (Scholl et al. 
1999, Wicki et al. 2006, Martin-Villar et al. 2015).  
Furthermore, the IC domain can be phosphorylated at the two conserved Ser sites by 
protein kinase A and by cyclin-dependent kinase 5 (Krishnan et al. 2013, Krishnan et al. 
2015)). The phosphorylation needs to occur on both sites in order to diminish cell motility. 
Whether this modification interferes with ERM protein binding or another mechanism 
resulting in reduced migration has not been addressed yet. 
The degradation of the ECM is a critical process for tumor cell invasion. Increased PDPN 
expression in epidermal tumor cells suggests a decisive role in tissue remodeling (Vinicius 
de et al. 2011, Martin-Villar et al. 2015). Martín-Villar and colleagues reported that ERM 
proteins mediate and stabilize PDPN in invadopodia (Martin-Villar et al. 2015). 
Invadopodia are actin-rich protrusions of the plasma membrane which are important for 
tumor cell invasion. Although the location of PDPN in these structures is dispensable for 
the formation, PDPN is required for invadopodia maturation (Martin-Villar et al. 2015). This 
process is regulated by the RhoC GTPase phosphorylates LIM kinases and subsequent 
cofilin dephosphorylation and activation (reviewed in Kanellos and Frame (2016)). The 
cofilin-mediated actin polymerization leads then to invadopodia stabilization.  
 
1.4.3 Transcriptional Regulation of Podoplanin 
PDPN is expressed in a variety of tissues and interacts with multiple partners in different 
context, hence, it could be expected that the PDPN promoter region is controlled by 
multiple context-specific signaling pathways and transcription factors. 
The transcription of PDPN was found in in vitro studies to be controlled by several growth 
factors (e.g. transforming growth factor beta (TGF-ȕ) and epidermal growth factor (EGF)) 
as well as cytokines (interferon gamma (IFN-Ȗ) and interleukin 6 (IL-6); reviewed in Renart 
et al. (2015), Quintanilla et al. (2019)).  
Besides others, the transcription factor activating protein 1 (AP-1) family can result in 
PDPN expression (Durchdewald et al. 2008). AP-1 members are comprised of homo- or 
heterodimers formed by Jun, Fos and activating transcription factor (ATF) proteins 
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mediating gene regulation in development and pathology as response to extracellular 
stimuli like cytokines, growth factors and chemical carcinogens (Angel et al. 2001, Eferl 
and Wagner 2003). AP-1 target genes are involved in cell differentiation, proliferation as 
well as cell-cell and cell-matrix interactions, respectively (reviewed in Angel et al. (2001)). 
Several in vivo studies highlight the important role of AP-1 transcription factors in the skin. 
Saez and colleagues reported that c-Fos is dispensable for physiological epidermal 
differentiation and first steps of tumor development, however, it is required for malignant 
tumor conversion (Saez et al. 1995). Regulating AP-1 activity during chemically induced 
skin tumorigenesis by a dominant negative Fos mutant revealed that AP-1 activity 
interferes with the development of benign or malignant squamous cell lesions (Gerdes et 
al. 2006). Durchdewald and colleagues used the K5-hSOS-F transgenic mouse model in 
combination with epidermal Fos deletion to screen for Fos-regulated genes in skin tumor 
development (Durchdewald et al. 2008). Using isolated RNA from generated PAP, Pdpn 
was detected as the highest differentially expressed gene in the performed global gene 
expression analysis indicating that PDPN is a direct Fos target. Moreover, protein 
expression analysis on tissue sections pf TPA-treated wild-type (WT) animals confirmed 
PDPN upregulation in tumor cells at the invasive front.  
 
The absence of PDPN in keratinocytes in healthy skin but its upregulation in transformed 
epidermal cells at the invasive tumor front implies a relevant involvement in cSCC 
progression. 
 
1.4.4 The Role of Podoplanin in Pathology 
In contrast to healthy skin, its expression is strongly induced under pathological conditions. 
In the process of wound healing, PDPN is upregulated in keratinocytes and fibroblasts 
(Honma et al. 2012, Baars et al. 2015). Despite the upregulation in the re-epithelizing 
wounded epidermis, in vitro and in vivo analysis showed that the loss of Pdpn in 
keratinocytes is not essential for wound healing and most likely, is compensated by yet to 
define mechanisms (Baars et al. 2015). Furthermore, in psoriatic hyperproliferative 
epidermis PDPN expression can be upregulated in basal cells (Honma et al. 2012). 
Diverse PDPN protein levels were observed in patients suffering from NMSC and CIS. 
PDPN was detected in around 30 % of BCC tumor cells, whereas PDPN expression was 
strongly increased in AK (~70 %) and cSCC (up to 90 %; Wicki and Christofori (2007), 
Wojciechowska-Zdrojowy et al. (2016)). In addition, stromal cells showed also a PDPN-
positive reaction: ~45 % in BCC, ~20 % in AK and ~80 % in cSCC (Wojciechowska-
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Zdrojowy et al. 2016). Notably, cSCC tumor cells and fibroblasts at the invasive front 
strongly upregulated PDPN (Figure 6 A; Gandarillas et al. (1997), Wicki and Christofori 
(2007), Vinicius de et al. (2011), Wojciechowska-Zdrojowy et al. (2016)). Clinical studies 
demonstrated that a strong expression of PDPN is associated with lymph node metastasis 
and consequently with poor prognosis in cSCC among other tumor types (Figure 6 B; 
Vinicius de et al. (2011), Wojciechowska-Zdrojowy et al. (2016)). In functional in vitro 
studies using human immortalized keratinocytes, mouse carcinoma as well as breast 
cancer cell lines, it was demonstrated that exogenous overexpression of PDPN results in 
enhanced migration and invasion (Scholl et al. 1999, Wicki et al. 2006). These data 
indicate a functional role of this glycoprotein in tumor cell migration and invasion. 
 
 
Figure 6 PDPN protein expression is associated with invasive growth and worse patient 
outcome. 
A) PDPN expression is strongly increased in cSCC tumor cells (brown signal). B) High PDPN 
expression in tumor cells of locally advanced cSCC is correlated with poor long-term survival. 
Adapted from Vinicius de et al. (2011) and Wojciechowska-Zdrojowy et al. (2016).  
 
In conclusion, as an AP-1 target gene the function of PDPN in cSCC has not been clarified 
yet, although in vitro and in vivo studies investigating its role in other SCC entities suggest 
increased tumor cell invasion, the causality of PDPN in keratinocyte tumors as well as the 
clinical suitability is still missing.  
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1.5 Aim 
Even though the cure rate of early-stage cSCC is high, there is still an immense amount 
of patients suffering from late-stage non-curable tumors. Moreover, certain lifestyle 
behaviors like sun tanning are still attractive, life expectancy is increasing and as this 
NMSC is a disease of the older-aged population, there will be a vast increase of cSCC 
patients in the next decades (Leiter et al. 2017, Nagarajan et al. 2018). Therefore, 
investigations are needed to identify possible therapeutic targets for novel therapies 
treating patients with cSCC.  
Experiments using exogenous overexpression of PDPN resulted in enhanced invasion and 
migration (Scholl et al. 1999, Martin-Villar et al. 2006, Wicki et al. 2006). Furthermore, 
PDPN is strongly expressed in cSCC, especially at the invasive front, and clinical data of 
advanced tumor stages has shown that high PDPN expression in cancer cells correlates 
with poor survival (Vinicius de et al. 2011, Wojciechowska-Zdrojowy et al. 2016). Although 
these studies suggest that PDPN expression in tumor cells can cause more aggressive 
and life-threatening cSCCs, these studies lack mechanistically the causality of PDPN 
expression and skin cancer cell migration and invasion and thus, worse clinical outcome.  
Therefore, I aimed to study the decisive impact of PDPN in the process of cSCC 
carcinogenesis, since its fundamental role during this process is still unknown. For this 
purpose an orthotopic in vivo mouse model as well as different functional in vitro assays 
were performed. These analyses addressed the functional consequences of 
CRISPR/Cas9-mediated PDPN deletion in human and murine cancer cells on tumor cell 
proliferation, migration and invasion to gain more understanding on the role of PDPN in 
skin carcinoma progression.  
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2 MATERIAL AND METHODS 
2.1 Materials 
2.1.1 Technical Equipment 
Animal Trimmer Aesculap® Isis   Braun, Suhl 
Axio Scan.Z1 Slidescanner    Zeiss, Oberkochen 
BD FACSAria I     Becton Dickinson, Heidelberg 
BD FACSAria Fusion II    Becton Dickinson, Heidelberg 
BD FACSCaliburTM     Becton Dickinson, Heidelberg 
BD LSR Fortessa HTS    Becton Dickinson, Heidelberg 
Cell incubator Heraeus HERA cell 240  Heraeus Instruments, Hanau 
Cell incubator Heraeus HERA cell 240i  Thermo Scientific, USA 
Cell incubator      Binder, Tuttlingen 
Centrifuge Biofuge Fresco    Heraeus Instruments, Hanau 
Centrifuge Biofuge 13     Thermo Scientific, USA 
Centrifuge Heraeus Megafuge 16    Thermo Scientific, USA  
Centrifuge Varifuge 3.0 R     Heraeus Sepatech, USA 
Centrifuge Heraeus Fresco17   Thermo Scientific, USA  
Cryo freezing container     Nalgene; Thermo Scientific, USA  
Cryotome CM3050S     Leica, Wetzlar 
Developer Classic E.O.S.     Agfa, USA  
Digital Caliper      RS Pro, Mörfelden-Walldorf 
Drying Cabinet     Heraeus Instruments, Hanau 
Electrophoresis chamber for SDS-PAGE   Bio-Rad Laboratories, Munich  
Embedding machine Tissue-Tek TEC  Sakura, USA 
Fine scale XS205 DualRange   Mettler Toledo, Gießen  
Heating mat       Conrad Electronic, Mannheim  
Heat plate Top Line 2000    Rommelsbacher, Dinkelsbühl 
Isoflurane gas vaporizer Vapor 19.3   Dräger, Lübeck 
Magnetic stirrer/heat plate IKA® BH basic 2 IKA, Staufen 
Magnetic stirrer/heat plate MR 2000   Heideloph, Schwabach  
Microliter syringe 705LT 50 µl   Hamilton Robotics, USA 
Microplate reader Clariostar     BMG Labtech, Ortenberg 
Microscope AX10     Zeiss, Oberkochen 
Microscope Leica DMLB     Leica, Wetzlar 
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Microscope Nikon Eclipse Ti    Nikon, Düsseldorf  
Microscope Olympus IX51    Olympus, Japan 
Microscope Zeiss LSM 700    Zeiss, Oberkochen 
Microtome RM2155      Leica, Bensheim  
Mircotome SM2010 R    Leica, Bensheim 
Mixing Block MB-102     Bioer, China 
Needle, 27 gauge beveled     World Precision Instruments, Berlin  
Orbital shaker, Minishaker MS1    IKA, Staufen  
pH meter 765 Calimatric    Knick, Berlin  
Pipettes (Pipetman)      Gilson, USA  
Pipettor accu-jet® pro     Brand, Wertheim  
Pipettor Pipetboy acu     Integra Biosciences, Switzerland  
Platform shaker Polymax 2040    Heidolph, Schwabach  
Power supply Power Pac 300/3000    Bio-Rad Laboratories, München  
Rotator/Shaker Rotoshake Genie    Scientific Industries, USA  
Scale BP4100      Sartorius, Göttingen  
Scale KERN® 440-47N    Kern & Sohn, Balingen 
Shaker       Multitron Infors, Schweiz  
Shaker SD5D      CAT Laboratories, Staufen 
Slide Staining Tray     Pyramid Innovation, UK 
Sterile GARD® Hood VBM600   Baker Company Inc., USA 
Surgical tools       Fine Science Tools, Heidelberg  
Thermomixer 5437      Eppendorf, Hamburg  
Vacuboy      Integra, USA 
Vortex IKA® MS 3 digital    IKA, Staufen 
Water bath       GFL, Burgwedel  
Water bath Ecoline 19    LAUDA Scientific, Lauda-Königshofen 
Water bath HI 1210     Leica, Wetzlar 
Wet blot transfer system     Bio-Rad Laboratories, USA 
Z2 Coulter Particle Count and Size Analyzer Beckman Coulter, USA 
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2.1.2 Consumables 
Cell culture plates (35 mm, 60 mm, 100 mm, Sigma-Aldrich, Steinheim; Corning, 
150 mm)     The Netherlands 
Cell scraper      Corning, The Netherlands 
Conical centrifuge tubes (15ml, 50ml)   Corning, USA  
Cover glasses      Menzel-Gläser, Braunschweig 
Coverslips      Thermo Scientific, USA  
Cryo TubeTM      Fisher Scientific, Schwerte 
Disposable pipettes (5 ml, 10 ml, 25 ml, 50 ml) Corning, The Netherlands 
Disposable scalpel      Feather, Japan 
EasystrainerTM Cell Sieves    Greiner Bio-One, Frickenhausen 
ELISA MicrolonTM 96-well plate clear  Greiner Bio-One, Frickenhausen 
FACS tubes round-bottom with cell-strainer  Corning, The Netherlands 
Filter pipette tips (10 μl, 20 μl, 200 μl)  Krisker, Steinfurt 
Filter pipette tips (1250 µl)    Nerbe Plus, Winsen 
HTS FluoroBlok Permeable Supports  Fisher Scientific, Schwerte 
ImmEdge PenTM      Vector Laboratories, USA  
Multiwell plates (48-well)    Greiner Bio-One, Frickenhausen 
Multiwell plates (6-well, 12-well, 24-well, 96-well) Corning, The Netherlands 
Object slides Superfrost® Plus    NeoLab Migge, Heidelberg  
Parafilm PM996      Bemis, USA  
Pasteur capillary pipettes    WU, Mainz  
Pipette tips (10 μl, 20 μl, 200 μl, 1000 μl)   Steinbrenner, Wiesenbach  
Reaction tubes (1.5 ml, 2 ml) Eppendorf, Hamburg; Sarstedt, 
Nürnberg  
RunBlue SDS Gel 10 %     Expedeon, UK 
Syringe filters 0.22 μm, 0.45 µm   Merck, Darmstadt  
ThinCertTM cell culture inserts   Greiner Bio-One, Frickenhausen 
ThinCertTM plate     Greiner Bio-One, Frickenhausen 
Tissue embedding medium Histo-Comp®  Vogel, Fernwald  
Tissue-Tek® Cryomold®    Sakura Finetek, Stauffen 
WhatmanTM Opitran BA-S83 nitrocellulose   GE Helthcare, Munich 
membrane 
WhatmanTM 3 MM paper     Whatman, Dassel  
Fuji Medical X-ray films    Fuji, Japan 
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2.1.3 Chemicals and Reagents 
Acetic acid      Merck, Darmstadt 
AEC+ High Sensitivity Substrate Chromogen Agilent Technologies, Waldbronn 
 Ready-to-use 
ATX Ponceau S Red Staining solution  Fluka, Buchs 
BD MatrigelTM Basement Membrane Matrix  BD Biosciences, Heidelberg 
Bovine serum albumin (BSA)    Sigma-Aldrich, Steinheim  
Bradford MX      Expedeon, UK 
Bromodeoxyuridine (BrdU)    BD Biosciences, Heidelberg  
Citric acid       AppliChem, Darmstadt 
Dimethylsulfoxide (DMSO)     Biomol, Hamburg 
Dispase II      Sigma-Aldrich, Steinheim 
Dithiothreitol (DTT)     AppliChem, Darmstadt 
Eosin B      Sigma-Aldrich, Steinheim 
Ethanol (EtOH)      VWR, France 
Ethylenediamine tetraacetate (EDTA)   Roth, Karlsruhe  
Eukitt®      Kindler, Freiburg 
FACS-Clean      BD Biosciences, Heidelberg 
FACS-Flow      BD Biosciences, Heidelberg 
FACS-Rinse      BD Biosciences, Heidelberg 
Fluorescence Mounting Medium   Agilent Technologies, Waldbronn 
Glycerol       AppliChem, Darmstadt 
Glycine       GERBU Biotechnik, Heidelberg  
Hematoxylin      Fluka, Buchs 
Hydrochloric acid (HCl)    Fisher Chemical, UK 
Hydrogen peroxide (H2O2)    AppliChem, Darmstadt  
Isopropanol (2-Propanol)    Fisher Chemical, UK 
Methanol (MetOH)     Fisher Chemical, UK  
Milk powder       Roth, Karlsruhe  
Monopotasium phosphate (KH2PO4)   Roth, Karlsruhe 
Mowiol 4-88      Roth, Karlsruhe 
Normal Goat Serum     Vector Laboratories, USA 
Nonidet P40 (NP-40)     Fluka, Buchs 
Nuclease-free water      Invitrogen, Kalsruhe; Qiagen, Hilden  
PageRulerTM Prestained Protein Ladder  Thermo Scientific, USA 
Paraffin       Vogel, Giessen  
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Paraformaldehyde (PFA)    Roth, Karlsruhe  
Phosphatase Inhibitor Cocktail II   Sigma-Aldrich, Steinheim 
Pierce Bovine Serum Albumin Standard  Life Technologies, Darmstadt 
 Pre-Diluted Set 
Polyethylenimin (PEI), linear, MW 25.000   Alfa Aesar, USA  
Polybrene      Merck, Darmstadt 
Potassium chloride (KCl)     Roth, Karlsruhe  
Protease Inhibitor Cocktail I    Sigma-Aldrich, Steinheim 
Proteinase K      Sigma-Aldrich, Steinheim 
Puromycin dihydrochloride    Life Technologies, Darmstadt 
RunBlue LDS Sample Buffer (4x)   Expedeon, UK 
RunBlue SDS Run Buffer TEO-Tricine  Expedeon, UK 
Sodium chloride (NaCl)    Fisher Chemical, UK 
Sodium citrate     Fluka, Buchs 
Sodium dihydrogen phosphate (NaH2PO4.2H2O) Fluka, Buchs 
Sodium dodecylsulfate (SDS)    GERBU Biotechnik, Heidelberg 
Sodium deoxycholate     Sigma-Aldrich, Steinheim 
Sodium hydroxide (NaOH) solution   Fluka, Buchs 
Tissue-Tek® O.T.C.TM Compound   Sakura Finetek, Staufen 
Tris-base       Sigma-Aldrich, Steinheim  
Tris-hydrochloride (Tris-HCl)    Roth, Karlsruhe  
Triton-X-100       AppliChem, Darmstadt  
Tween-20       AppliChem, Darmstadt  
Xylene       VWR, France 
 
2.1.4 Buffers and Solutions 
Table 2 Composition of buffers and solutions. 
Buffer Composition 
Blocking buffer I 5 % (v/v) normal goat serum 
2 % (v/v) BSA  
PBS, 1x 
Blocking buffer II  10 % (v/v) normal goat serum 
1 % (v/v) BSA 
PBS, 1x 
Blocking buffer III  5 % (w/v) milk powder 
TBST, 1x 
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Buffer Composition 
Blocking buffer IV 10 % (v/v) normal goat serum 
3 % (v/v) BSA 
PBS, 1x 
Citrate buffer, pH 6 1.8 mM citric acid 
8.2 mM sodium citrate 
FACS buffer 1 % (v/v) BSA 
PBS, 1x 
HCl, 2 N 0.17 % (v/v) HCl, 37 % 
Mowiol mounting medium 6 g Mowiol 4-88 
6 g glycerol 
6 ml H2O 
PBS, 10x pH 7.2 1.5 M NaCl 
27 mM KCl 
82 mM Na2HPO4.2H2O 
17 mM KH2PO4 
Permeabilization buffer 10 % (v/v) normal goat serum 
2% (v/v) BSA 
0.1 % (v/v) Triton-X-100 
PBS, 1x 
PFA, 4 % pH 7.4 5 N NaOH 
20 g PFA 
1 l PBS, 1x 
RIPA buffer 50 mM Tris-HCl, pH 8 
150 mM NaCl 
0.1 % (v/v) SDS 
0.5 % (v/v) sodium deoxycholate 
1 % (v/v) NP-40 
TBS, 10x pH 7.6 0.2 M Tris-base 
1.37 M NaCl 
TBST, 1x 0.5 % (v/v) Tween-20 
10 % (v/v) TBS, 10x 
Triton/PBS, 0.3 % 0.3 % (v/v) Triton-X-100 
10 % (v/v PBS, 10x) 
Western blot transfer buffer, 10x 0.25 M Tris-base 
1.9 M glycine 
Western blot transfer buffer, 1x 20 % (v/v) MetOH 
10 % (v/v) Western blot transfer buffer, 10x 
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2.1.5 Oligonucleotides 
Table 3 Sequences of guide RNAs. 
Target Sequence 5’-3’ 
Renilla luciferase CACCGGGTATAATACACCGCGCTAC 
PDPN exon 1 (KO2) CACCGGCCTGGAGGAGCGCGACGGT 
PDPN exon 2 (KO1) CACCGAGACTTATAGCGGTCTTCGC 
Pdpn exon 1 CACCGCTCCCGAGCTCTTCCCGGCT 
 
2.1.6 Plasmids 
Table 4 List of plasmids. 
Name Company 
lentiCRISPRv2 Addgene #52961 
pCMV-VSV-G Addgene #8454 
psPAX2 Addgene #12260 
pUltra-hot (mCherry) Addgene #24130 
pUltra-hot-V5-Firefly-luciferase-mCherry (V5) Addgene #24130 + V5-tagged luciferase 
excised from #19166 using XbaI and NheI 
 
2.1.7 Primary Antibodies 
Table 5 Antibodies used for flow cytometry. 
Antigen Clone Conjugate Concentration Company/catalogue number 
PDPN NC-08 Alexa 647 4 µl/1x106 cells BioLegend® #337008 
PDPN 8.1.1 APC 0.024 µg/5x105 cells BioLegend® #127409 
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Table 6 Antibodies utilized for immunohistochemistry and immunofluorescence. 
Antigen Clone Host 
species 
Dilution Antigen retrieval Company/ 
catalogue number 
BrdU Ab-3 mouse 1:100 Citrate buffer pH 6 Merck, #NA61 
Cleaved 
caspase 3 
D175 rabbit 1:200 Citrate buffer pH 6 Cell Signaling #9661 
Cytokeratin 
pan 
polyclonal rabbit 1:150 Citrate buffer pH 6 Progen #10550 
E-cadherin 36 mouse 1:100 Citrate buffer pH 6 BD Biosciences 
#610181 
Ezrin monoclonal mouse 1:100 Citrate buffer pH 6 Santa Cruz #sc-32759 
Keratin 5 polyclonal rabbit 1:100 Citrate buffer pH 6 Biolegend #905501 
Keratin 14 LL002 mouse 1:500 Citrate buffer pH 6 
EDTA pH 8 
Abcam #7800 
Ki67 polyclonal rabbit 1:500 Citrate buffer pH 6 Abcam #15580 
mCherry polyclonal rabbit 1:300 Proteinase K Abcam #167453 
Laminin polyclonal rabbit 1:200 EDTA pH 8 Abcam #11575 
PDPN D2-40 mouse 1:100 Citrate buffer pH 6 BioLegend® #916002 
PDPN 8.1.1 Syrian 
hamster 
1:100 Citrate buffer pH 6 Hybridoma Bank 
Vimentin ERP3776 rabbit 1:500 Citrate buffer pH 6 Abcam #92547 
V5 poly29038 rabbit 1:100 Citrate buffer pH 6 BioLegend® #903801 
 
Table 7 Primary antibodies utilized for Western blotting. 
Antigen Clone Host species Dilution Company/catalogue number 
Cas9 7A9.3A3 mouse 1:2000 Cell Signaling #14697 
Cyclophilin A polyclonal rabbit 1:1000 Cell Signaling #2175S 
HDAC2 C-8 mouse 1:2000 Santa-Cruz #sc-9959 
mCherry polyclonal rabbit 1:100 Abcam #167453 
PDPN D2-40 mouse 1:1000 BioLegend® #916602 
PDPN 8.1.1 Syrian hamster 1:2000 Hybridoma Bank 
V5 monoclonal mouse 1:5000 Thermo Scientific #R960-25 
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2.1.8 Secondary Antibodies 
Table 8 Secondary antibodies used for immunohistochemistry and immunofluorescence. 
Antigen Host species Dilution Conjugate Company/catalogue number 
Mouse IgG goat 1:200 biotin Vector Laboratories #BA-2000 
Mouse IgG goat 1:500 Alexa 488 Invitrogen #A11001 
Mouse IgG goat 1:500 Alexa 647 Invitrogen #A21235 
Rabbit IgG goat 1:200 biotin Vector Laboratories #BA-1000 
Rabbit IgG donkey 1:500 Alexa 488 Invitrogen #A21206 
Rabbit IgG goat 1:500 Alexa 546 Invitrogen #A11010 
Rabbit IgG goat 1:500 Alexa 647 Invitrogen #A21244 
Syrian 
hamster IgG 
goat 1:200 biotin Jackson ImmunoResearch 
#107-065-142 
Syrian 
hamster IgG 
goat 1:500 Alexa 488 Dianova #107-547-142 
Syrian 
hamster IgG 
goat 1:200 Cy3 Jackson ImmunoResearch 
#107-165-142 
Syrian 
hamster IgG 
goat 1:200 Cy5 Dianova #705-176-147 
 
Table 9 Secondary antibodies used for Western blotting. 
Antigen Host species Dilution Conjugate Company/catalogue number 
Mouse IgG horse 1:2000 HRP Cell Signaling #7076S 
Rabbit IgG goat 1:2000 HRP Cell Signaling #7074S 
Syrian 
hamster IgG 
goat 1:2000 HRP Jackson ImmunoResearch 
#107-065-142 
 
2.1.9 Reagents for Immunofluorescence and Flow Cytometry 
Table 10 Substances used for immunofluorescence and flow cytometry. 
Compound Dilution Company/catalogue number 
4-chlorobenzenesulfonate salt (DiD) 4 µl/million cells Biotium #60014 
Hoechst 33342 1:1000 Chemodex #CDX-B0030 
Propidium iodide (PI) 1:1000 BioLegend® #421301 
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2.1.10 Commercially Available Kits 
Cell Proliferation Kit XTT    AppliChem, Darmstadt 
DAB Peroxidase Substrate Kit   Vector Laboratories, USA 
Enhanced Chemiluminescence (ECL) Substrate PerkinElmer, USA  
VECTASTAIN® Elite® ABC HRP Kit  Vector Laboratories, USA 
Venor® GeM Classic Kit    Minerva biolabs®, Berlin 
 
2.1.11 Human Skin Samples 
Human skin samples of healthy and diseased skin were kindly provided by Dr. Doris Helbig 
(University Clinic for Dermatology and Venerology, Cologne).  
 
2.1.12 Cells and Cell Lines  
Table 11 Primary cells. 
Name Species Description Provenience 
hDF human normal human dermal fibroblasts, female 
donor, 23 years old 
Petra Boukamp lab, 
DKFZ Heidelberg 
 
Table 12 Established human and murine cell lines. 
Name Species Description Reference 
BDVII mouse DMBA-induced cSCC Fusenig et al. (1978) 
HEK-293T human embryonic kidney  - 
MET-4 human cSCC metastasis, lymph node, p53 WT Popp et al. (2000), Proby 
et al. (2000) 
SCL-II human primary cSCC, face, p53 mutant Tilgen et al. (1983) 
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2.1.13 Cell Culture Media and Supplements 
Table 13 Cell culture conditions. 
Cells Condition Medium Medium composition Company/catalogue number 
hDF 37 °C, 
5 %CO2 
D10 DMEM 
10 % FBS 
1 % L-glutamine 
Sigma-Aldrich #D5671 
Sigma-Aldrich #F7524 
Sigma-Aldrich #G7513 
BDVII 37 °C, 
5 %CO2 
D10+2 DMEM 
10 % FBS 
2 % L-glutamine 
Sigma-Aldrich #D5671 
Sigma-Aldrich #F7524 
Sigma-Aldrich #G7513 
HEK-293T 
MET-4 
SCL-II 
37 °C, 
8 %CO2 
D10 DMEM 
10 % FBS 
1 % L-glutamine 
Sigma-Aldrich #D5671 
Sigma-Aldrich #F7524 
Sigma-Aldrich #G7513 
 
Table 14 Cell culture reagents. 
Name Company/catalogue number 
Opti-MEM® Reduced Serum Medium Life Technologies #31985 
Poly-L-lysine solution Sigma-Aldrich #P4707 
Penicillin/Streptomycin (P/S) Sigma-Aldrich #P4333 
Trypan Blue Sigma-Aldrich #93595 
 
Table 15 Culture media and solutions. 
Medium Composition Company/catalogue number 
CDM DMEM, DMEM:F12 (1:1) 
10 % FBS 
1 % P/S/A 
200 µg/ml 2-phospho-L-ascorbic acid 
1 ng/ml rh TGF-ȕ1 
2.5 ng/ml rh EGF 
5 ng/ml rh FGF-2 
5 µg/ml rh insulin 
Lonza #BE12-604F, #BE12-719F 
Sigma-Aldrich #F7524 
Lonza #17-745E 
Sigma-Aldrich #49752 
Life Technologies #PHG9214 
PromoCell #C-60170 
PromoCell #C-60240 
Sigma-Aldrich #91077C 
Freezing 
Medium 
DMEM 
20 % FBS 
1 % L-glutamine 
10 % glycerol 
Sigma-Aldrich #D5671 
Sigma-Aldrich #F7524 
Sigma-Aldrich #G7513 
AppliChem #A3092 
DPBS/EDTA DPBS 
 
EDTA 0.5 M 
PAN Biotech #P04-36500,  
Sigma-Aldrich #D8537 
self-made 
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Medium Composition Company/catalogue number 
rFAD DMEM, DMEM:F12 (1:1) 
10 % FBS 
1 % P/S/A 
200 µg/ml 2-phospho-L-ascorbic acid 
0.4 µg/ml hydrocortisone 
10-10 M Cholera toxin 
Lonza #BE12-604F, #BE12-719F 
Sigma-Aldrich #F7524 
Lonza #17-745E 
Sigma-Aldrich #49752 
Sigma-Aldrich #H4001 
Sigma-Aldrich #C8052 
Trypsin/EDTA DPBS 
 
EDTA 0.5 M 
Trypsin 
PAN Biotech #P04-36500, 
Sigma-Aldrich # D8537 
self-made 
Pan-Biotech #P10-822100 
 
2.1.14 Mice 
Female NMRI nude mice (Rj:NMRI-Foxn1nu/nu) were purchased from Janvier Laboratories 
(Saint Berthevin Cedex, France). 
 
2.1.15 Software 
Adobe Illustrator     Adobe System, USA 
BD FACSDivaTM BD Biosciences, Heidelberg 
EndNote v.X7 Adept Scientific GmbH, Frankfurt am 
Main 
FlowJo V10      Tree Star, Inc., USA 
GIMP 2.10.8      Das GIMP-Team 
GraphPad Prism 7.05    GraphPad Software, Inc., USA 
ImageJ      National Institute of Health, USA 
Inkscape 0.92.3     Inkscape Project, USA 
NIS Element AR 4.13.04    Nikon, Darmstadt 
Office 2013      Microsoft, USA 
StepOneTM Software v2.2.2    Life Technologies, USA 
Zen 2.3 (Blue edition)     Zeiss, Oberkochen  
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2.2 Methods 
2.2.1 Animal Experiments 
2.2.1.1 Housing of Mice 
All experiments were reviewed and approved by the local government authority for animal 
experimentation (Regierungspräsidium Karlsruhe, Germany). Mice were housed in a 
specific pathogen-free environment in the animal facility at controlled temperature of 21 °C, 
50-60 % humidity and 12 h time-controlled light cycles (DKFZ, Heidelberg, Germany). 
Food and drinking water was supplied ad libitum.  
 
2.2.1.2 Orthotopic Injection of Tumor Cells 
Female 6-8 weeks old NMRI nude mice (Rj:NMRI-Foxn1nu/nu) were used for intradermal 
(i.d.) injection of labeled murine BDVII cSCC cells with or without specific Pdpn deletion 
under the approved license #G-75/17. The BDVII cell line was generated from DMBA-
induced mouse skin carcinomas in C57BL/6 mice (Fusenig et al. 1978). Mice were 
anesthetized using isoflurane (O2 flow 2 l/min, 1.5-2 Vol% isoflurane). A heating mat 
ensured maintenance of mouse body temperature during the procedure. To prevent eyes 
from dehydration, they were covered with eye ointment. Single cell suspension of labeled 
BDVII WT, Cas9 control or Pdpn KO cells (2x 106 diluted in 20 µl sterile DPBS) were i.d. 
injected into the right flank of the animals using a 27 G Hamilton syringe.  
Tumor growth was checked by measuring tumor length (L) and width (W) with a digital 
caliper at least three times per week starting from seven days after tumor cell injection 
until mice were sacrificed. Tumor volume was calculated according to the formula given 
below (Equation 1). For final tumor measurement all three dimensions were determined 
(Equation 2). 
Equation 1 Formula for calculation of tumor volume during observation period. 
L = maximum tumor length, W = tumor width orthogonally to maximum tumor length. tumor volume = Ͳ.5 ×  L ×  W2 
 
Equation 2 Formula for final tumor volume calculation. 
L = maximum tumor length, W = tumor width orthogonally to maximum tumor length, H = tumor 
height.  tumor volume ሺfinalሻ = L ×  W ×  H 
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CO2 inhalation was used to sacrifice mice at indicated time points after tumor cell injection 
or when termination criteria were reached. Death of mice was determined by lacking 
reflexes (eyes and toes). To assess proliferating tumor cells, BrdU was intraperitoneally 
injected (100 µg/g body weight) into mice four hours prior to euthanization. Developed 
tumors were resected with surrounding tissue, fixed and embedded for further analysis 
(paragraph 2.2.3). 
 
2.2.2 Cell culture  
2.2.2.1 Thawing and Cryopreserving Cells 
All cell stocks were stored in cryovials in -80 °C freezer. Cell stocks were thawed at 37 °C 
in a water bath, gently mixed and added to pre-warmed cell type-specific medium in 10 cm 
cell culture dishes. Cells were cultured according to section 2.2.2.2 and 2.2.2.3. 
For cryopreservation, cells were harvested and dissociated (paragraph 2.2.2.2 and 
2.2.2.3). Cells were counted with a Z2 Coulter Particle Count and Size Analyzer and 
centrifuged at 1300 rpm for 3 min. After aspirating the supernatant, the cell pellet was 
resuspended in freezing medium at 2x 106 cells in 1.8 ml (1.1x 106 cells/ml). Aliquoted 
cryovials were cryopreserved using a Cryo Freezing Container o/n at -80 °C. Frozen cell 
stocks were stored long-term in -80 °C freezer. 
 
2.2.2.2 Culture and Passaging of Primary Fibroblasts 
Normal human dermal fibroblasts (hDFs) were cultured in D10 medium at 37 °C, 5 % CO2, 
20 % O2 in humid incubators (Table 13). Culture medium was refreshed every other day. 
Reaching confluence, hDFs were washed with DPBS/EDTA and detached with 
Trypsin/EDTA by 5 min incubation at 37 °C. By adding D10 medium hDFs were gently 
detached, singularized and counted using Z2 Coulter Particle Count and Size Analyzer. 
hDFs were subcultured in D10 medium with 3-5x 105 cells per 15 cm cell culture dish. 
 
2.2.2.3 Culture and Passaging of Established Cell Lines 
Details of used human and murine cell lines are listed in table 13. The murine cSCC cell 
line BDVII and generated subclones were cultured in D10+2 medium at 37 °C, 5 % CO2, 
20 % O2 in humid incubators. Human cell lines HEK-293T, SCL-II, MET-4 and all 
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corresponding generated sublines were cultured in D10 medium at 37 °C, 8 % CO2, 
20 % O2 in humid incubators. Medium was changed every other day.  
For cultivating, HEK-293T cells were washed with DPBS/EDTA followed by detaching 
using Trypsin/EDTA for 2 min incubation at 37 °C. The reaction was stopped by adding 
D10 medium. Cells were gently detached, singularized and subcultured. All other cell lines 
were initially washed with DPBS, followed by treatment with DPBS/EDTA for cell type-
specific incubation times (5-20 min at 37 °C). Trypsin/EDTA solution was added for 
incubation up to 5 min at 37 °C. Dissociation was stopped by adding cell type-specific 
medium. Cells were singularized and subcultured. All cells were subcultured at 
subconfluence. 
All experiments were performed using cell passage between two and ten after thawing. 
 
2.2.2.4 Contamination Control 
Cell lines were tested regularly for mycoplasma contaminations. Therefore, medium which 
had been on cultured cells for at least two days was used and processed according to the 
Venor® GeM Classic Kit. Tests were performed by Melanie Sator-Schmitt.  
 
2.2.2.5 Cell Culture Microscopy 
All monolayer cultures were routinely checked for cell morphology and cellular growth as 
well as for bacterial or fungal contaminations using an Olympus IX51 microscope. 
 
2.2.2.6 Lentivirus Production 
For the stable transfer of desired CIRSPR/Cas9 construct or maker (Table 4), established 
cSCC cell lines were lentivirally transduced (Table 13). Therefore, HEK-293T cells were 
subcultured (section 2.2.2.3) and seeded in D10 medium on one 10 cm cell culture dish 
with a density of 2.5x 106 cells per one transfection condition. Cells grew 50 % confluence 
after o/n incubation; culture medium was refreshed 2 h prior to transfection. Every 
transfection mixture was prepared as the following: 3x transfection reagent 
polyethylenimin (PEI) was added to Opti-MEM® Reduced Serum Medium followed by 
adding DNA (Table 16).  
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Table 16 Composition of transfection mixture for lentivirus production. 
Opti-MEM® PEI [1 mg/ml] pCMV-VSV-G psPAX2 Plasmid of interest 
200 µl 21 µl 2 µg 1 µg 4 µg 
 
After 15 min incubation at room temperature (RT), the transfection mixture was added 
drop-wise to cells. Transfected HEK-293T cells were subsequently transferred to an S2 
laboratory for o/n incubation at 37 °C, 5 % CO2, 20 % O2. Culture medium was changed 
the following morning. 24 and 48 h later, virus-containing medium was harvested and 
filtered through a 0.4 µm strainer. Virus-containing medium was stored at 4 °C for 
maximum one week. 
 
2.2.2.7 Lentiviral Transduction of Cutaneous Squamous Cell Carcinoma Cells 
For lentiviral transduction, human and murine cSCC cells were seeded onto 10 cm cell 
culture dishes after cells were harvested (section 2.2.2.3). Following steps were performed 
in a S2 laboratory. After 24 h incubation cSCC cells reached 50 % confluency and culture 
medium was exchanged by virus-containing medium supplemented with polybrene 
(1:1000) and incubated o/n. Virus-containing medium was exchanged by cell type-specific 
medium the next morning and cells were left for additional 24 h for resting. After intensive 
washing with DPBS transduced cells were transferred to an S1 laboratory and subcultured. 
 
2.2.2.8 Transient Transfection of Cutaneous Squamous Cell Carcinoma Cells 
To delete Pdpn in murine cSCC cells using the CRISPR/Cas9 technology without 
continuous Cas9 expression, BDVII cells were transfected. Thus, for every transfection 
condition, 2x 105 BDVII cells were seeded onto one 10 cm cell culture dish. Transfection 
was performed on the next day as described (section 2.2.2.6). Table 17 is displaying the 
composition of used transfection mixture, whereas plasmid of interest in table 4. After 
transfection tumor cells were cultivated in an S1 laboratory. 
Table 17 Mixture used for cSCC cell transfection. 
Opti-MEM®  PEI [1 mg/ml] Plasmid of interest 
200 µl 24 µl 8 µg 
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2.2.3 Histological Methods  
2.2.3.1 Fixation, Paraffin or Cryo Embedding and Sectioning 
Tumor with surrounding tissue isolated from mice as well as samples of the 3D SCM were 
fixed in 4 % PFA solution o/n at 4 °C (tumor samples) or RT (3D culture samples), 
respectively, followed by o/n incubation in 70 % ethanol at 4 °C. Samples were transferred 
into tissue cassettes and processed for paraffin embedding using the Tissue-Tek® VIP™ 
5 Jr. Vacuum Infiltration Processor with an automated program protocol (Table 18). For 
embedding in paraffin, samples were taken out of plastic cassettes and transferred into 
metal molds filled with liquid paraffin using a Tissue-Tek® TEC™ Tissue Embedding 
Console. Solidified paraffin blocks were stored at 4 °C until sectioning. 4-6 µm sections 
were cut by Sabrina Lohr, Angela Funk, Angelika Kritschke or by myself using sliding 
microtomes SM2010R or RM2155. Sections were smoothened in a 42 °C water bath and 
transferred to SuperFrost® slides followed by a drying incubation at 42 °C o/n. Sections 
were stored at RT until staining. 
Table 18 Processing of tissue before paraffin embedding.  
Automated program of Tissue-Tek® VIP 5 Jr. Vaccuum Infiltration Processor. 
Step Temperature [°C] Cycles Time [min] 
70 % EtOH 35 1 45 
80 % EtOH 35 1 90 
90 % EtOH 35 2 90 
96 % EtOH 35 2 90 
Isopropanol 35 2 90 
Xylene 40 2 150 
Paraffin 60 4 45 
 
Depending on used antibody, murine material needed to be embedded into Tissue-Tek® 
O.C.T.™ Compound into Cryomolds®. Embedded samples were frozen using dry ice and 
stored at -80 °C until usage. Cryo-embedded samples were pre-warmed to -20 °C and cut 
into 6 µm section using the Cryotome CM3050S. 
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2.2.3.2 Tissue Preparation for Stainings 
Paraffin was removed from paraffin-embedded sections by washing twice with xylene (8 
and 5 min) followed by rehydration using an ethanol series of 2 min incubation steps each 
(96 %, 80 %, 70 %, 60 % in water) and 2 min incubation with distilled water.  
Frozen sections were thawed at RT for 20 min followed by fixation with 4 % PFA for 15 min 
at RT. 
 
2.2.3.3 Hematoxylin and Eosin Staining 
Hematoxylin staining of paraffin-embedded as well as frozen sections was performed for 
6 min followed by washing in running water for 8 min. Sections were stained in eosin for 
6 min and washed in running water for 6 min. Sections were dehydrated in 2 min 
80 % ethanol, 2 min 90 % ethanol followed by 2 min isopropanol and 2x 5 min xylene. 
Finally, sections were mounted in Eukitt®. 
 
2.2.3.4 Immunohistochemistry of Paraffin-Embedded Sections 
For immunohistochemical (IHC) staining antigen retrieval was performed on rehydrated 
sections corresponding to used antibodies listed in table 6. 
(i) Citrate buffer or EDTA: 500 ml citrate buffer or 1 mM EDTA solution was boiled in a 
glass beaker on a heating plate. Deparaffinized and rehydrated sections were 
incubated in sub-boiling retrieval solution for 15 min or 8 min, respectively. Glass 
beaker was removed from the heating plate and left at RT for cooling down for 
15 min. 
(ii) Protease K: sections were incubated with 20 µg/ml protease K for 20 min at 37 °C.  
After antigen retrieval, sections were washed in PBS and encircled with a hydrophobic 
barrier ImmEdge PenTM followed by another washing in PBS. For all following incubation 
steps, sections were placed into a humid chamber and sections were washed in PBS 
between incubations. Sections were incubated light-protected with 3 % H2O2 solution for 
10 min at RT to block endogenous peroxidase. Subsequently, sections were blocked in 
blocking buffer II for 30 min at RT. Primary antibodies were diluted in blocking buffer II and 
sections were incubated o/n at 4 °C (Table 6). One section per experiment was left in 
blocking buffer II without primary antibody and served as staining control. Biotin-linked 
secondary antibody staining was performed light-protected with secondary antibody 
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(Table 8) diluted in blocking buffer II 1 h at RT. Meanwhile, avidin/horseradish peroxidase 
(HRP) was prepared according to manufacturer’s instructions (VECTASTAIN® ABC-Elite 
reagent) and used for the next incubation for 30 min at RT. Further, the signal was 
developed using γ’-diaminobenzidine (DAB) reagent, which was prepared as designated 
in the manufacturer’s protocol. The reaction of DAB staining was monitored using the Leica 
DMLB microscope and stopped with tap water when the signal was sufficiently visible. Cell 
nuclei were counterstained with hematoxylin for 30 s to 2 min, dehydrated and mounted 
as described in paragraph 2.2.3.3. Sections were stored at RT until imaging.  
Sections were additionally treated for BrdU staining. After H2O2 incubation, 0.3 % 
Triton/PBS was applied to sections for 10 min at RT followed by 20 min incubation at 37 °C 
with 2 N HCl. Blocking and antibody staining were performed as described. Instead of the 
DAB reagent, staining was developed utilizing AEC substrate and after hematoxylin 
staining sections were mounted using fluorescent mounting medium.  
 
2.2.3.5 Immunofluorescent Staining of Tissue and 3D Culture Samples 
Rehydration and antigen-retrieval of paraffin-embedded sections were performed as 
described (section 2.2.3.2 and 2.2.3.4). Sections were placed in a humid chamber for all 
incubation steps of the immunofluorescence (IF) staining and washed in between with 
PBS. After blocking sections with blocking buffer II for 30 min at RT, o/n incubation at 4 °C 
was performed applying primary antibody dilutions in blocking buffer II (Table 6). One 
section per experiment was left in blocking buffer II without primary antibody and served 
as staining control. On the following day, sections were stained light-protected with 
fluorophore-labeled secondary antibodies diluted in blocking buffer II for 1 h at RT (Table 
8). Additionally, cell nuclei were stained light-protected with Hoechst 33342 solution 
(1:1000) for 5 min at RT. Finally, sections were mounted in fluorescent mounting medium 
and stored light-protected at 4 °C until imaging. 
Sections were differently treated for Laminin-K14 co-staining. After antigen retrieval 
sections were washed twice in TBST (0.1 % Tween 20) followed by 15 min incubation in 
0.2 % Tritin-X-100 in TBS. Sections were blocked in blocking buffer IV for 1 h at RT and 
primary antibodies were diluted in blocking buffer II and incubated o/n at 4 °C (Table 6). 
One section per experiment was left in blocking buffer II without primary antibody and 
served as staining control. All following washing steps were performed in three-times for 
10 min in TBS. Incubation with secondary antibodies was performed in blocking buffer II 
for 1 h at RT light-protected (Table 8). Cell nuclei were stained light-protected with 
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Hoechst 33342 solution (1:1000) for 5 min at RT. Finally, sections were mounted in 
fluorescent mounting medium and stored light-protected at 4 °C until imaging. 
 
2.2.4 Protein Biochemistry Methods  
2.2.4.1 Immunofluorescence Staining of Cultured Cells 
Cells were seeded on poly-L-lysine-mounted coverslips placed into 48-well plates and 
cultured in cell type-specific medium until cells reached desired density (section 2.2.2.3). 
For fixation, medium was removed and cells were fixed with 4 % PFA for 20 min at RT. 
After washing with PBS, coverslips were placed in a humid chamber for all incubation 
steps and washed in between with PBS. Cells were permeabilized and blocked in parallel 
with permeabilization buffer for 30 min at RT. Incubation with primary antibody dilutions in 
blocking buffer I (Table 6) was performed o/n at 4 °C. One coverslip per experiment was 
left in blocking buffer I without primary antibody and served as staining control. On the 
following day, cells were stained light-protected with fluorophore-labeled secondary 
antibodies diluted in blocking buffer I for 1 h at RT (Table 8). Additionally, cell nuclei were 
stained light-protected with Hoechst 33342 solution (1:1000) for 5 min at RT. Finally, 
coverslips were mounted face-down on microscope slides in Mowiol solution and stored 
light-protected at 4 °C until imaging. 
 
2.2.4.2 Preparation of Protein Extracts 
Confluent grown cells were washed once with cold PBS. Cells were lysed in cell lysis buffer 
(Table 18) and transferred into a 1.5 ml reaction tube. After centrifugation (20 min, 
13 000 rpm, 4 °C), supernatant containing isolated whole cell protein extracts were 
transferred to a new reaction tube and stored at -80 °C. 
Table 19 Composition of cell lysis buffer for protein extraction. 
Reagent Amount 
RIPA buffer 979 µl 
Protease Inhibitor Cocktail I 10 µl 
Phosphatase Inhibitor Cocktail II 10 µl 
DTT 1 µl 
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2.2.4.3 Determination of Protein Concentration 
Protein concentration of cellular extracts was quantified according to the Bradford assay. 
Lysates were diluted 1:5 in water. To define the standard curve a PierceTM Bovine Serum 
Albumin (BSA) Standard Pre-Diluted Set was used. Water was used as blank. Duplicates 
of each sample and standard were prepared in a transparent 96-well plate and Bradford 
MXTM solution was added. Absorbance was detected with a microplate reader at 595 nm 
wavelength. Final protein concentrations were calculated by the BSA standard curve. 
 
2.2.4.4 Protein Separation with SDS-PAGE 
The concentration of protein extracts was equally set to either 20 or 30 µg and 
supplemented with 4x RunBlue LDS Sample Buffer followed by denaturation for 10 min at 
95 °C. Samples were cooled down to 4 °C and loaded onto a pre-casted 10 % RunBlue 
SDS gel. The PageRuler™ Prestained Protein Ladder was additionally loaded for size 
comparison. SDS gel was placed into an SDS-PAGE chamber filled with 1x RunBlue SDS 
Run Buffer. Electrophoretic separation of proteins was achieved by applying a current of 
80 V for the first 10 min followed by 120 V for full separation.  
 
2.2.4.5 Western Blotting 
Separated proteins were transferred from separation gel onto nitrocellulose membranes 
using a wet blotting system. Therefore, the gel and WhatmanTM nitrocellulose membrane 
were embedded between two pre-moistened sheets of WhatmanTM 3MM paper on each 
side. Proteins were transferred at 400 mA for 2 h at 4 °C. Successful protein transfer to 
the nitrocellulose membrane was confirmed by Ponceau staining followed by washing with 
tap water. To avoid unspecific protein binding, the membrane was blocked with blocking 
buffer III for 1 h at RT followed by o/n incubation at 4 °C with primary antibody diluted in 
blocking buffer III (Table 7). On the next day, the membrane was washed with 1x TBST 
buffer and membrane was stained with HRP-linked secondary antibody diluted in blocking 
buffer III at RT for 1 h (Table 9). Membrane was washed with 1x TBST. Enhanced 
chemiluminescence (ECL) solution was prepared according to the manufacturer’s protocol 
and distributed equally over the membrane. Protein signals were detected using x-ray films 
and the Developer Classic E.O.S machine.  
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2.2.5. Flow Cytometry and Fluorescence Activated Cell Sorting 
2.2.5.1 Flow Cytometric Analysis 
2D-cultured cells were harvested and single cell suspensions were counted using the Z2 
Coulter Particle Count and Size Analyzer. For flow cytometric analysis, 5x 105 cells were 
resuspended in FACS buffer and incubated for 20 min at 4 °C light-protected with 
appropriate antibody (Table 5). Cells were washed and resuspended in 250 µl FACS 
buffer. Protein expression was analyzed using BD FACSCaliburTM or LSR Fortessa HTS. 
Analysis was performed using the FlowJoV10 Program or BD FACSDivaTM Software.  
 
2.2.5.2 Fluorescence Activated Cell Sorting 
For the generation of polyclonal PDPN KO cultures derived from the PDPN KO-transduced 
cells, PDPN KO and WT cells (PDPN-positive control) were expanded and singularized 
(section 2.2.2.3). Cells were counted using the Z2 Coulter Particle Count and Size 
Analyzer, resuspended in FACS buffer and stained with the species-specific fluorophore-
labeled anti-PDPN antibody at 4 °C for 20 min in the dark (Table 5). Afterwards, cells were 
washed with DPBS, resuspended in FACS buffer and dead cells were stained with PI 
(1 µl/ml cell suspension). Cell suspensions were transferred to FACS tubes by filtering 
through 0.35 µm sieves. Cells were transported to the Flow Cytometry Facility (DKFZ, 
Heidelberg, Germany), who performed the bulk sort to establish PDPN-negative cell 
population using the BD FACSDivaTM Software. After sorting, cells were centrifuged 
(1300 rpm, 3 min) and cultured in D10 supplemented with 1 % P/S. After one week, 
medium was exchanged to D10 and cells were expanded and cryopreserved (paragraph 
2.2.2.1). 
In order to establish BDVII WT, Cas9 control and Pdpn KO cultures expressing either V5-
Firefly-luciferase-mCherry or mCherry marker, these cell lines were FACSorted for 
mCherry after lentiviral transduction (paragraph 2.2.2.7). Cells were prepared and sorted 
as described with one exception: no PI staining was performed. mCherry-positive cells 
were cultivated in medium supplemented with 1 % P/S for one week and expanded for 
cryopreservation (section 2.2.2.1).  
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2.2.6 Functional Analyses 
2.2.6.1 Proliferation Assay 
Control and PDPN KO human and murine cSCC cell lines were seeded as triplicates for 
each time point onto 12-well plates and incubated as described (section 2.2.2.3). Cells 
were harvested 24, 48 and 72 h after seeding. Single-cell suspensions of triplicates were 
used to assess proliferation by counting. Cells were counted manually using the Neubauer 
chamber and trypan blue to identify dead cells (Equation 3). Experiments were run three 
times in triplicates. Two-tailed Welch’s t test was used to determine potential differences 
in proliferation. Significant differences were considered with p < 0.05. 
Equation 3 Formula for determination of total cell amount. 
Cell number was calculated using the Neubauer Chamber. Z = amount of counted cells. total cell amount = Z  x ͳͲ4 
 
2.2.6.2 Viability Test 
To assess metabolically active cells the Cell Proliferation Kit XTT was performed according 
to the manufacturer’s protocol. Therefore, human and murine control and PDPN KO cell 
lines were seeded onto transparent flat-bottomed 96-well plates in cell type-specific 
medium. Wells only containing medium were used as blank displaying background control. 
Viability was detected 24, 48 and 72 h after cell seeding. To this end, XTT reaction solution 
was prepared just prior to use and added to cultured cells. After 2 h incubation time in a 
humid incubator, the absorbance of samples (460 nm) against background control 
(660 nm) was detected. Experiments were run three times in triplicates. Two-tailed Welch’s 
t test was used to determine potential differences in metabolic activity. Significant 
differences were considered with p < 0.05. 
 
2.2.6.3 Boyden Chamber Transmigration Assay 
Human and murine cSCC PDPN KO cells and corresponding Cas9 controls were seeded 
as triplicates onto 6-well plates under cell type-specific culture conditions (section 2.2.2.3). 
After o/n culture, cells with ~50 % density were starved using starvation medium (culture 
medium without FBS) and incubated for another 24 h. On the following day 24-well HTS 
FluoroBlok cell culture inserts with an 8 µm filter were coated with 0.2 mg/ml BD Matrigel™ 
and incubated 1 h at RT. Meanwhile, cSCC cells were harvested, singularized in starvation 
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medium and labeled with the hydrophobic marker DiD (Table 10). Therefore, cells were 
counted using the Z2 Coulter Particle Count and Size Analyzer and incubated with DiD in 
starvation medium for 20 min at 37 °C followed by washing with DPBS. Cells were 
resuspended in starvation medium with 2.5x 105 cells/ml. Cell culture inserts were 
transferred to a 24-well plate prepared with 500 µl/well cell line-specific medium 
supplemented with FBS and 200 µl cSCC cell suspension was added drop-wise on 
matrigel-coated inserts. Cells were incubated with cell line-specific conditions in humid 
incubators. Transmigration was monitored regularly by DiD stained cells which reached 
the bottom of the filter inserts using the Nikon Eclipse Ti microscope. Optimal cell line-
specific incubation time was determined according to transmigrated control cells during 
the first performance of the experiment.  
After cell line-specific incubation, cells were fixed light-protected with 4 % PFA for 20 min 
at RT followed by washing with PBS. Non-transmigrated cells on top of the filter were 
removed with a Q-tip. Filters were cut out of inserts and placed bottom-to-top into a humid 
chamber for IF staining which was performed as described (section 2.2.4.1). Instead of 
permeabilization buffer, blocking buffer I was used for the blocking step. After the staining 
procedure filters were transferred to a microscope slide and mounted using Mowiol 
solution and 12 mm coverslips. Transmigrated cells were detected using the Nikon Eclipse 
Ti microscope. Transmigrated cells were automatically quantified by Hoechst staining 
using an ImageJ macro written by myself. Experiments were run three times in technical 
triplicates. To see whether transmigratory capacity was affected by the loss of PDPN, two-
tailed Welch’s t test was performed. Differences in transmigration were considered 
significant with p < 0.05. 
 
2.2.6.4 Organotypic Skin Cancer Model 
The organotypic skin cancer model (SCM) is a 3D culture system based on fibroblast-
derived matrix (fdm) with keratinocytes or cSCC cells growing air-exposed on top of hDFs 
within a deep-well system (Figure 4). This experiment was performed as published by 
Berning et al. (2015).  
For the generation of fdm, low-passage hDFs were expanded until a sufficient number of 
cells were grown (paragraph 2.2.2.2). hDFs were seeded step-wise within the first week. 
In detail, 5x 105 hDFs were seeded three times in CDM medium onto one 12-well 
ThinCert™ cell culture insert with a density of 0.4 µm pores. The filter inserts were placed 
into deep-well plates prepared with CDM medium and cultured at 37 °C, 5 % CO2, 20 % O2. 
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CDM medium was changed in the deep-well and in the filter insert every other day for four 
weeks. 
After four weeks murine or human cSCC cells were added on top of the generated fdm. 
Therefore, medium in deep-well was changed to rFAD medium and medium on top of 
hDFs was removed. cSCC cells were harvested and single-cell suspensions were 
provided after cells were strained through a 70 µl cell sieve. 2.5x 105 tumor cells were 
seeded onto hDFs and incubated at 37 °C, 5 % CO2, 20 % O2. Medium was refreshed 
every other day until defined time points were reached. After the first five days, medium 
on top of the cells was completely removed, so that cSCC cells were growing air-exposed. 
Experiments were run once with one to three technical replicates for human cell lines for 
each time point. For each time point the experiment was performed three times with 
technical triplicates for murine cSCC cells.  
For the harvest, organotypic co-culture samples on filters were removed from inserts and 
cut in half. One half was fixed in 4 % PFA and embedded in paraffin, the filter membrane 
of the bottom side of the other half was removed and the sample was embedded into 
Tissue-Tek® O.C.T.™ Compound and stored at -80 °C until usage (section 2.2.3.1).  
 
2.2.7 Image Acquisition and Analysis 
Images were captured using the Nikon Eclipse Ti microscope, confocal Zeiss LSM 700 
microscope or the Axio Scan.Z1. ImageJ or Zen Blue software were used for image 
processing adjusting brightness, contrast and gamma. Images were quantified using 
macros for ImageJ software written by myself together with Dr. Damir Krunic, Light 
Microscopy Facility (DKFZ, Heidelberg, Germany).  
 
2.2.8 Statistical Analysis 
To determine potential differences of tumor volumes between two groups (control and 
Pdpn KO group), tumor volumes were plotted and statistically compared by the 
implementation of the one-tailed Mann-Whitney test. For the identification of the significant 
difference between the means of two groups (control and Pdpn KO group), the two-tailed 
Welch’s t test was performed.  
Analyses were done using GraphPad Prism 7.05 Software. Dr. Tim Holland-Letz was 
consulted for the definition of group sizes for the animal license and Thomas Hielscher 
aided the statistical analysis of performed functional in vitro and in vivo experiments. 
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3 RESULTS 
3.1 Varying Podoplanin Protein Expression in Different Cell 
Types of Patients Suffering from Different Skin Diseases 
As podoplanin (PDPN) has been proposed as a major driver in the progression of different 
cancer entities including cutaneous squamous cell carcinoma (cSCC), this study aimed to 
define this proposed function in cSCC progression. Moreover, previous publications had 
shown that PDPN is expressed in varying intensities by different cell types in healthy and 
diseased skin (section 1.4.1 and 1.4.4). Thus, to validate and further extend our knowledge 
the location and expression levels of PDPN in physiology and pathology, 
immunohistochemistry (IHC) staining of human tissue sections of healthy skin as well as 
of multiple pathological diseases was performed. 
Confirming published data, PDPN was weakly expressed in healthy skin by some basal 
keratinocytes, whereas dermal fibroblasts were negative for PDPN (Figure 7 A; 
Gandarillas et al. (1997)). Moreover, lymphatic vessels, hair roots and sebaceous glands 
showed a PDPN-positive reaction. Staining of the inflammatory skin diseases Lichen 
Planus Ruber and eczema showed an increased PDPN expression in basal keratinocytes 
as well as in fibroblasts suggesting that fibroblasts were in an activated state (Figure 7 B 
and C). PDPN-positive fibroblasts were also detected in skin affected by the auto-immune 
disease psoriasis (Figure 7 D; Honma et al. (2012)). Particularly, in psoriasis PDPN was 
strongly upregulated in basal keratinocytes compared to healthy skin. The potential 
precancerous stage of cSCC can be actinic keratosis (AK), which showed a prominent 
PDPN expression in basal keratinocytes of the hyperactive epidermis (Figure 7 E). In 
descriptive cSCC analysis, PDPN expression was only described in poor- to moderate-
differentiated tumors (Schacht et al. 2005, Vinicius de et al. 2011). In contrast, I found that 
tumor cells of six moderate (n=1) to well-differentiated cSCC (n=5) highly expressed PDPN 
at the invasive front suggesting that PDPN is involved in differentiated tumors as well 
(Figure 7 F). Interestingly, a PDPN-positive reaction with varying intensities was also 
detected in CAFs in six out of six analyzed tumor samples. 
In conclusion, PDPN protein expression levels as well as location differed in health and 
disease conditions and among analyzed diseases. In comparison to other skin diseases, 
cSCC tumor cells showed constantly strong PDPN expression, especially at the invasive 
front. This observation suggested a crucial role of this glycoprotein in differentiated cSCC. 
Moreover, a PDPN-positive reaction was detected in the tumor stroma as well. These 
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results indicated that PDPN might act as a driver in the process of tumor cell invasion in 
differentiated cSCC.  
 
 
Figure 7 Differential PDPN protein expression in healthy and diseased skin.  
Human PDPN expression was determined by IHC staining. A) In healthy skin PDPN was focally 
expressed in basal keratinocytes (arrowheads) and showed stronger expression in lymphatic 
vasculature (LV), hair root (R) and sebaceous glands (Sb). B) and C) Lichen Planus Ruber and 
escema displayed stronger PDPN expression in basal keratinocytes and fibroblasts 
(arrowheads). D) Expression of PDPN in psoriasis was strongly increased in basal keratinocytes 
and showed a weak positive staining in fibroblasts (arrowheads). E) In AK enhanced PDPN 
expression was detected in basal keratinocytes of the hyperactive epidermis. F) PDPN was 
highly expressed in tumor cells (T) at the invasive front of cSCC. CAFs showed weak PDPN 
staining (arrowheads) in the stroma (St). Representative images are shown. N=6 cSCC. Nuclei 
were stained with hematoxylin. Scale bar 200 µm, image quality was optimized by adjustment 
of brightness, contrast and gamma. 
 
3.2 Podoplanin Acts as a Driver in Cutaneous Squamous Cell 
Carcinoma in Vitro 
The descriptive analysis of PDPN protein expression in well-differentiated cSCC patients’ 
material implied a critical role of PDPN in tumor cell invasion. However, functional 
experiments were necessary to conclude on the causality of PDPN expression and cSCC 
progression. So far it has only been shown that PDPN upregulation by exogenous 
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overexpression increases cell migration in immortalized mouse keratinocytes as well as in 
breast cancer cell lines (Scholl et al. 1999, Wicki et al. 2006). To investigate the importance 
of PDPN loss in cSCC cancer cells on the invasive capacity in functional in vitro and in 
vivo experiments, a loss-of-function (LOF) approach was used by applying the 
CRISPR/Cas9 technology on human and murine cSCC cell lines.  
 
3.2.1 Selection of Human and Murine Cell Lines 
Several cell lines displaying different cSCC stages have been established which can be 
used in in vitro and in vivo approaches (section 1.2.1). For the establishment of PDPN-
deficient cSCC tumor cells, the CRISPR/Cas9 technology with subsequent bulk 
fluorescent activated cell sort (FACSort) was chosen. As PDPN is a transmembrane 
protein a PDPN-negative polyclonal cell culture can be generated with this approach while 
avoiding single cell clones and potential related clonal artifacts. For this procedure, PDPN 
needed to be expressed by tumor cells in monolayer culture condition and thus, its 
expression had to be determined initially in potential candidate cell lines.  
Therefore, whole-cell protein lysates of 2D-cultured human and murine cSCC cell lines 
derived from various cSCC tumors or metastasis were used for Western blotting (Figure 
8 A and B). Detected intensities of PDPN protein expressions varied between different 
human cSCC cell lines. Moreover, this analysis demonstrated a shift of electrophoretic 
mobility of PDPN suggesting potential cancer-specific posttranslational modifications such 
as glycosylation. The human SCL-II and MET-4 cell lines were selected based on their 
tumor origin, PDPN expression intensity and diverse electrophoretic shift. SCL-II cells 
were isolated from a facial undifferentiated primary tumor and MET-4 cells were 
established from an undifferentiated metastatic cSCC (Tilgen et al. 1983, Popp et al. 2000, 
Proby et al. 2000). Thus, these two selected human cell lines represent tumors at different 
stages of cSCC progression. Comparing these two lines, MET-4 cells expressed lower 
PDPN levels as SCL-II cells, but the electrophoretic mobility of PDPN was shifted in SCL-
II cells probably due to differential glycosylation patterns. Besides human cSCC cells, the 
murine cSCC cell line BDVII was chosen allowing syngeneic injections into mice. This cell 
line was generated by chemical induction of cSCC in C57BL/6 mice (Fusenig et al. 1978). 
BDVII cells strongly expressed PDPN (~ 42 kDa) and its electrophoretic mobility was 
shifted differently compared to SCL-II and MET-4 cells (~55 kDa and ~49 kDa, Figure 8 A 
and B). Notably, the expression intensity between human and murine PDPN cannot be 
compared as different antibody clones (human D2-40 and murine 8.1.1) were used for the 
detection.   
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Figure 8 PDPN protein expression in human and murine cSCC cell lines. 
Western blot analysis of 2D-cultured A) human cell lines and B) murine BDVII cells showed 
varying protein levels. Protein expression of HDAC2 and Cyclophilin A were used as loading 
control. C) Representative images of histological and IF analysis of PDPN expression of 
selected human and murine cell lines in the 3D organotypic SCM. All tumor cells formed multiple 
epithelial layers and invaded into the dermal compartment. Different PDPN expression pattern 
was observed. Nuclei were stained with Hoechst. Scale bar 100 µm, image quality was 
optimized by adjustment of brightness, contrast and gamma. 
 
The expression levels of PDPN were additionally analyzed in 3D context using the 
organotypic skin cancer model (SCM). SCL-II, MET-4 and BDVII cells were seeded on top 
of human dermal fibroblasts (hDFs) and cultured for two weeks. Histological analysis 
showed that tumor cells grew on top of the dermal compartment reflecting the 
characteristics of original tumor samples (Figure 8 C; Tilgen et al. (1983), Popp et al. 
(2000), Proby et al. (2000)). SCL-II and MET-4 cells formed a multilayered epithelium 
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without differentiation, whereas BDVII cells formed cornified layers. IF staining 
demonstrated that PDPN expression was not only restricted to invasively growing cells. 
All SCL-II cells expressed PDPN homogenously on a moderate level, whereas only a 
proportion of MET-4 cells showed PDPN staining in different intensities. In the murine 
BDVII culture, PDPN was strongly expressed in all active tumor cells, but it was gradually 
lost when cells entered terminal differentiation. 
Hence, the two human SCL-II and MET-4 as well as the murine BDVII cSCC cell lines 
were selected. Their origin, the differences in PDPN expression intensities as well as 
potential different glycosylation patterns made these cell lines particular attractive to 
investigate the causative link between PDPN expression and cSCC progression. 
 
3.2.2 Establishment of Podoplanin Deletion in Human and Murine 
Cutaneous Squamous Cell Carcinoma Cell Lines 
3.2.2.1 Generation of Podoplanin Knockout and Control Cells 
To examine the impact of PDPN loss in tumor cells on the invasive potential in functional 
in vitro and in vivo experiments, the CRISPR/Cas9 system was chosen to constitutively 
ablate PDPN in selected human and murine cSCC cell lines. PDPN-deficient and control 
cells were generated in a multistep procedure (Figure 9). Accordingly, SCL-II, MET-4 and 
BDVII cells were transduced with the lentiviral vector lentiCRISPRv2 encoding the 
endonuclease Cas9 and a guide RNA (gRNA) specifically targeting either human PDPN 
or murine Pdpn. To delete PDPN in human cell lines two gRNAs were transduced targeting 
two different exons of PDPN generating two sublines (PDPN knockout 1 (KO1) and KO2, 
Table 4, Figure 9 A). To generate murine Pdpn-deficient cells one gRNA was used (Figure 
9 B). Moreover, appropriate Cas9-expressing control cells (ctrl) were generated in parallel 
to exclude potential effects of Cas9 in further experiments. Therefore, human and murine 
cSCC cells were lentivirally transduced with Cas9 as described, but here a gRNA was 
utilized which targeted a Renilla-luciferase gene originated from sea pansy. Subsequently, 
all transduced sublines were treated with puromycin for one week to select cells which 
stably integrated the construct.  
To distinguish murine BDVII tumor cells upon injection from host cells, BDVII wild-type 
(WT), control and Pdpn KO cells were additionally labeled with the V5-Firefly-Luciferase-
mCherry (V5) via lentiviral transduction followed by bulk FACSort (Figure 9 B).  
To evaluate successful PDPN deletion as well as marker expression, PDPN protein and 
marker expression were verified on protein level on a single cell level.  
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Figure 9 In vitro generation of PDPN KO and control cells. 
CRSPR/Cas9-mediated PDPN KO and generation of Cas9-expressing controls (ctrl) in 
A) human and B) murine cSCC cells using lentiviral infection. Additional labeling of murine BDVII 
cells. Validation of PDPN and marker expression was performed on protein level.  
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3.2.2.2 Validation of Podoplanin and Marker Expression in Generated Human and 
Murine Cutaneous Squamous Cell Carcinoma Cell Lines 
After generation of polyclonal PDPN KO and control sublines, the presence or absence of 
PDPN protein expression, respectively, as well as labeling of the BDVII-V5 cells were 
validated by immunofluorescence (IF) staining and FACS analysis.  
To verify PDPN protein levels an IF staining of cultured cells was performed. Strong PDPN 
expression was found in BDVII WT- and control-V5 cells (Figure 10 A). No PDPN was 
observed in the KO-V5 culture. SCL-II WT and control cells expressed PDPN at a 
moderate level, whereas KO1 and KO2 showed no PDPN signal (Figure 11 A). MET-4 
control cells showed varying PDPN levels. Single cells expressing low levels of PDPN 
were detected in MET-4 KO cultures (Figure 11 A arrowheads).  
In order to test whether generated PDPN KO cultures retained their PDPN-negative status 
over time, FACS analyses at different time points were performed. Nearly 100 % of BDVII 
WT- and control-V5 cells showed high PDPN expression (Figure 10 B and C). Pdpn KO-
V5 cells maintained around 3 % PDPN-expressing cells over several passages. 
Furthermore, analysis of mCherry expression revealed that more than 90 % of all murine 
sublines were positive for the introduced marker. SCL-II WT and control cells expressed 
PDPN on a moderate level (Figure 10 B and D). Notably, SCL-II KO1 and KO2 cultures 
contained less than 3 % of PDPN-positive cells from low to high culture passage (Figure 
11 B and D). PDPN-positivity in MET-4 WT and control cells ranged from 55 to 90 % 
(Figure 11 C and D). In generated MET-4 KO1 and KO2 cultures, the proportion of PDPN-
positive cells increased over time from 1 % to around 11-14 %. Although an additional 
FACSort of MET-4 KO cultures could have lowered the remaining PDPN-positive 
population, this procedure was left out to retain a short cultivation period. In consequence, 
low passage cultures were used for subsequent functional analyses. The residual small 
amount of PDPN-expressing cells in all generated KO sublines was taken into account. 
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Figure 10 Validation of PDPN and marker expression in murine cSCC cells. 
A) PDPN expression was observed by IF staining. WT- and control (ctrl)-V5 cells showed strong 
PDPN expression. No PDPN signal was detected in KO-V5 cells. B) FACS analysis confirmed 
PDPN-positive population in WT- and ctrl-V5 cultures. The small amount of PDPN-positive cells 
in KO-V5 subline was retained from early to late passages. WT-, ctrl- and KO-V5 cells expressed 
moderate to high mCherry levels. C) Overview of percentage portion in quadrant 1 to 4 (Q1-4) 
in early and late culture passages. Nuclei were stained with Hoechst. Scale bar 50 µm, image 
quality was optimized by adjustment of brightness, contrast and gamma. 
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Figure 11 PDPN protein evaluation in human cSCC cell lines. 
A) IF assessment of PDPN in SCL-II and MET-4 cells. FACS analysis of B) SCL-II and C) MET-
4 cells. SCL-II WT and control (ctrl) cells showed moderate PDPN expression, no IF staining 
was detected in KO1 and KO2 sublines. PDPN-positive cells in KO cultures remained below 
3 %. MET-4 WT and ctrl cells expressed varying PDPN levels and only single cells in KO1 and 
KO2 showed low PDPN expression (arrowheads) in early passage with was increasing over 
time. D) Overview of percentage portion in early and late culture passages. Nuclei were stained 
with Hoechst. Scale bar 50 µm, image quality was optimized by adjustment of brightness, 
contrast and gamma. 
 
Moreover, I further examined whether the cellular morphology in monolayer-cultured cells 
was changed upon PDPN deletion as it was already demonstrated that the loss of this 
protein can result in a change from the epithelial morphology to a more mesenchymal-like 
phenotype (reviewed in Lamouille 2014). Bright-field microscopy depicted that all 
established cells showed similar morphology (Figure 12). Neither the lack of PDPN nor the 
constitutive Cas9 expression in control cells resulted in different cellular morphology.  
 
 
Figure 12 Morphological analysis of generated PDPN KO and control sublines. 
A) Human and B) murine cSCC cells showed similar cobblestone-like morphology despite 
constitutive Cas9 expression and deletion of PDPN. Scale bar 50 µm, image quality was 
optimized by adjustment of brightness, contrast and gamma. 
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Taken together, applying the CRISPR/Cas9 technology human as well as murine PDPN 
KO and Cas9 control sublines were successfully established. Generated PDPN-proficient 
and -deficient SCL-II, MET-4 and BDVII cells are suitable for different functional in vitro 
experiments to examine differences in proliferation, migration and invasion. Moreover, the 
effect of PDPN on these tumor characteristics will be tested in an orthotopic mouse model 
applying murine BDVII cells. 
 
3.2.3 Functional Investigation of Podoplanin Loss in Cutaneous Squamous 
Cell Carcinoma Cell Lines in Vitro 
The impact of PDPN on cSCC proliferation was not defined yet. Performing different in 
vitro experiments, no difference in proliferation was described upon Pdpn loss in primary 
murine keratinocytes, whereas the downregulation of PDPN in human oral SCC (OSCC) 
cells was associated with reduced proliferation (Baars et al. 2015, Tsuneki et al. 2013). 
Additionally, migration and invasion were proposed as crucial tumor characteristics related 
to PDPN expression (Martin-Villar et al. 2006, Wicki et al. 2006). Hence, these three 
aspects were examined by employing generated human and murine cSCC cell lines.  
 
3.2.3.1 Loss of Podoplanin neither Influences Cell Proliferation nor Viability in 2D 
Culture System1 
Cell proliferation was determined by manual cell counting using the Neubauer Chamber 
combining with trypan blue staining to exclude dead cells. Cell viability was examined by 
employing the XTT assay in which cellular metabolic activity is detected by absorbance 
measurement. Proliferation and viability of human and murine cSCC cell lines were 
observed on three consecutive days. Manual counting as well as measurement of 
absorbance revealed that the cell number and metabolic activity in all cell lines was 
increasing over time (Figure 13 A and B; Schneider, 2019). In SCL-II and BDVII-V5 cells 
PDPN KO resulted in similar cell numbers and absorbance signal compared to control 
cells. Similar results were obtained for MET-4 cells (data not shown). Moreover, similar 
cell numbers were already observed after 24 h indicating indirectly that there was no effect 
on adhesion upon PDPN abrogation, since not attached cells would have been washed 
off the cell culture plate during the preparation for cell counting. 
                                               
1
 These experiments were performed by Jakob Schneider as part of his Bachelor thesis supervised by myself. 
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Figure 13 PDPN deletion neither affected proliferation nor viability in human and murine 
cSCC cells. 
A) Proliferation was examined by manual counting using the Neubauer chamber and trypan blue 
to identify dead cells. B) XTT assay was performed to determine cell viability. Both tests were 
done 24, 48 and 72 h after cell seeding. Cell amount and viability were increasing over time in 
human and murine cSCC cells. No difference was obtained comparing KO with control (ctrl). 
Values are plotted as mean and SD of n=3 independent experiments with technical triplicates. 
Unpaired two-tailed Welch’s t test was performed with a 95 % confidence level. N.s. not significant. 
 
3.2.3.2 Impact of Podoplanin on Cellular Transmigration 
In order to examine the possible rate limiting function of PDPN on the migratory potential 
of cSCC cells, the Boyden Chamber Matrigel (BCM) assay was performed using 
generated human and murine PDPN KO and Cas9 control cells. Tumor cells were seeded 
on top of matrigel-coated filters and cell line-specific incubation time allowed 
 
RESULTS 
 
 
67 
 
 
 
line 
RESULTS 
 
 
68 
Figure 14 Examination of the transmigratory capacity upon the loss of PDPN in cSCC cell 
lines.  
A) In the BCM assay matrigel was used as an artificial BM through which tumor cells needed to 
transmigrate according to a serum gradient (FBS). Transmigrated cells were stained for PDPN 
and Hoechst. Hoechst staining was utilized for automatic counting of transmigrated cells. 
B) Transmigrated control (ctrl) cells expressed PDPN. No PDPN signal was detected in 
transmigrated KO cells. C) PDPN loss in human SCL-II and MET-4 cells did not affect 
transmigration. Contrary, the deletion of Pdpn in murine BDVII cells resulted in a significant 
reduction. Values are plotted as mean and SD of n=3 independent experiments with technical 
triplicates. 5 fields per technical replicate were analyzed. Unpaired two-tailed Welch’s t test was 
performed with a 95 % confidence level. N.s. not significant, *** p < 0.001. Scale bar 100 µm, 
image quality was optimized by adjustment of brightness, contrast and gamma. 
 
cells to transmigrate through the Matrigel layer according to a serum gradient (Figure 
14 A). Transmigrated cells were stained for PDPN protein expression to verify its absence 
in KO sublines. Nuclei of transmigrated cells were stained with Hoechst and counted 
automatically utilizing a macro in ImageJ.  
In agreement of initial characterization (Figure 10 and 11), no PDPN expression was 
detected in either transmigrated KO sublines, whereas control cells express PDPN (Figure 
14 B). The transmigration of SCL-II cells was inefficient as only 50 cells per square 
millimeter migrated through the matrigel. In contrast, MET-4 cells showed a stronger 
transmigratory ability with more than 200 cells per square millimeter. The deletion of PDPN 
in human cSCC cell lines showed similar transmigratory capacity as control cells (Figure 
14 C).  
In comparison, the murine BDVII control-V5 cells showed similar transmigration potential 
as MET-4 cells. In murine cells, the loss of Pdpn resulted in a significant reduction of 
transmigration (200 to 50 cells/mm2; Figure 14 C). 
Since the deletion of PDPN showed different transmigratory effects in human compared 
to murine cSCC cells, the invasive capacity of all selected cancer cells was tested in the 
more complex fibroblast-derived matrix (fdm)-based SCM. Furthermore, this organotypic 
culture system reflects better physiological aspects.   
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3.2.3.3 Tumor Cell Invasion upon Podoplanin Deletion Using the Organotypic Co-
Culture System 
To study PDPN-dependent tumor cell invasiveness more profoundly and to complement 
already obtained results, the 3D organotypic SCM was used (Figure 4; Berning et al. 
(2015)). Control and PDPN KO cells derived from SCL-II, MET-4 and BDVII cell lines were 
seeded on top of the dermal equivalent generated by multiple seeding steps of hDFs. 
Cultures were cultivated up to four weeks and morphology was examined at different time 
points using histological and IF staining.  
In the organotypic model system, both human cell lines formed a multilayered epithelial 
compartment with no sign of differentiation reflecting the histology of original tumor 
samples (Figures 15 and 16; Tilgen et al. (1983), Popp et al. (2000), Proby et al. (2000), 
Berning et al. (2015)). IF assessment of SCL-II control cells showed only moderate PDPN 
expression in all tumor cells (Figure 15). Only focal PDPN expression was detected in 
MET-4 control cells (Figure 16). These results confirmed 2D culture properties of PDPN 
expression. Moreover, PDPN was expressed by either control cell lines independent of 
invasive behavior. No PDPN signal was detected in KO cells. Some single PDPN-positive 
tumor cells were observed in MET-4 KO1, even though early passaged cells were applied. 
Visual analysis of 3D culture sections showed that SCL-II and MET-4 tumor cells grew 
invasively into the dermal equivalent independent of PDPN expression confirming BCM 
data (Figure 14). This invasive growth was increasing over time. In SCL-II cultures small 
cell groups were detected indicating collective tumor cell invasion. MET-4 cells invaded as 
single cells.  
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Figure 15 No effect of PDPN loss in human SCL-II cells cultured in the SCM.  
Histological and IF stainings showed multilayered epithelium with no sign of differentiation. 
Invasive SCL-II tumor cell growth into the dermal equivalent increasing over time was observed 
which was independent of PDPN expression. Control (ctrl) cells expressed moderate PDPN and 
no PDPN expression was detected in KO1 or KO2. Pan Cytokeratin (pCK) was used as epithelial 
cell marker. Nuclei were stained with Hoechst for nuclear counterstain. Dashed line represents 
BM. N=1 with 1-3 technical replicates. Representative images are displayed. Scale bar 100 µm, 
image quality was optimized by adjustment of brightness, contrast and gamma. HE hematoxylin 
and eosin, w weeks. 
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Figure 16 PDPN deletion did not interfere human MET-4 cell invasion in 3D context.  
MET-4 control (ctrl), KO1 and KO2 tumor cells formed a multilayered epithelium without 
cornification and invaded into the dermal compartment assessed by HE and IF. Invasion was 
increasing over time in a PDPN-independent manner. Ctrl cells expressed varying PDPN levels 
and no PDPN expression was observed in KO2. Single KO1 cells showed a PDPN-positive 
reaction (arrowheads) Epithelial cells were stained with pan Cytokeratin (pCK). Hoechst was 
used for nuclear counterstain. Dashed line represents BM. N=1 with 1-3 technical replicates. 
Representative images are displayed. Scale bar 100 µm, image quality was optimized by 
adjustment of brightness, contrast and gamma. HE hematoxylin and eosin, w weeks. 
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Figure 17 Pdpn loss in murine BDVII-V5 cells diminished tumor cell invasion in the 3D 
model. 
Histological and IF assessment revealed formation of multilayered epithelium with terminal 
differentiation independent of PDPN expression. Tumor cells grew invasively into dermal 
compartment increasing over time and formed horn pearls. KO cells invaded less. Proliferative 
active control (ctrl) cells expressed high PDPN, whereas no PDPN was observed in differen-
tiated cells. KO cells did not express PDPN. K14 was used as epithelial cell marker. Hoechst 
was used for nuclear counterstain. Dashed line represents BM. N=3 with technical triplicates. 
Representative images are displayed. Scale bar 100 µm, image quality was optimized by 
adjustment of brightness, contrast and gamma. HE hematoxylin and eosin, w weeks. 
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Cultured murine BDVII-V5 cells revealed that these cells formed a fully differentiated 
multilayered epithelium over time independent of PDPN expression (Figure 17). These 
characteristics resembled the histology of original tumors (Fusenig et al. 1978). Tumor 
cells invaded collectively as tumor buds were observed in the dermal compartment. Larger 
areas of invaded cells showed cornified regions. Strong PDPN expression was observed 
in non-differentiated V5-labeled control tumor cells, whereas Pdpn KO-V5 cells showed 
no PDPN-positive staining. Notably, the visual examination of tissue sections revealed that 
Pdpn loss in BDVII-V5 cells resulted in reduced invasion confirming the findings of the 
BCM experiment (Figure 14). The time point of two weeks indicated already this difference 
between KO and control cultures, which became more obvious after four weeks of culture.  
 
In conclusion, the lack of PDPN did neither influence proliferation nor viability of cSCC 
tumor cells. However, the transmigratory and invasive capabilities of human and murine 
cSCC cells studied in the BCM assay and the SCM differed upon PDPN abrogation. The 
loss of Pdpn in the BDVII-V5 cells resulted in decreased transmigration and invasion in in 
vitro assays. Thus, to further characterize PDPN-dependent migratory behavior in 
functional experiments, the differences between Pdpn KO and control cells originated from 
the murine BDVII cell line became the focus of the following investigation. 
 
3.2.3.4 Quantitative Analysis of Podoplanin-Dependent Invasion of BDVII Cells in the 
3D Model 
I showed that the invasive behavior of cSCC cancer cells depended on PDPN expression. 
Consequently, the extent of tumor cell invasion was quantified and several 
immunostainings were performed to characterize tumor properties in the organotypic 
system.  
 
3.2.3.4.1 Decreased Invasion in Tumor Cells Lacking Podoplanin  
To verify the visual impression of reduced invasion of Pdpn KO compared to control BDVII-
V5 cells in the SCM (Figure 17), a quantitative analysis based on HE staining was 
performed. Therefore, bright-field images were used to execute semi-automated 
quantification using ImageJ. In this macro, the basement membrane (BM) was drawn 
manually. Tumor cells located below this set line and within the dermal equivalent were 
defined as invaded cancer cells. Tissue above the BM was excluded from the analysis. 
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Based on eosin staining of histological analysis (Figure 17), invaded tumor cells depicted 
a higher contrast compared to extracellular matrix (ECM) and hDFs. This property was 
used to quantify tumor cell invasion as area of tumor cells and distance which were 
covered by them.  
Statistical analysis revealed that the deletion of Pdpn in BDVII-V5 cells resulted in 
significant decreased invasive area compared to control-V5 cells at any assessed time 
point (Figure 18 A). Moreover, the distance of invaded V5-marked KO cells was diminished 
in average and KO cells invaded less deep into the dermal compartment compared to 
control-V5 cells (Figure 18 B and C).  
Taken together, the findings of the simplified transmigration assay (Figure 14) as well as 
of the more sophisticated 3D organotypic SCM (Figure 17) highlighted a driving role of 
PDPN in cSCC invasion.  
 
Figure 18 Tumor cell invasion was 
significantly reduced upon Pdpn deletion 
in the SCM. 
The loss of Pdpn in BDVII-V5 cells diminished 
A) the mean area, B) the covered mean 
distance and C) the maximum distance of 
invaded tumor cells. Values are plotted as 
mean and SD of n=3 independent experiments 
with technical triplicates. 3-5 fields per 
technical replicate were analyzed. Unpaired 
two-tailed Welch’s t test was performed with a 
95 % confidence level. N.s. not significant, 
* p < 0.05, ** p < 0.01, *** p < 0.001, w week 
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3.2.3.4.2 Loss of Podoplanin Does Not Affect Tumor Cell Proliferation2 
Besides collective tumor cell invasion, increased proliferation is changing multicellular 
positioning (Friedl et al. 2012). Tumor cells which are located at the periphery are pushed 
into the stroma due to expansive growth (Friedl et al. 2012). In order to determine whether 
increased proliferation of PDPN-expressing cells accounted for the increased invasive 
phenotype, Ki67 as proliferative marker was assessed. 
Based on visual analysis no difference in the amount of Ki67-positive tumor cells was 
observed between Pdpn-proficient and -deficient BDVII-V5 cells at any time point 
(Figure 19, Schneider 2019). 
These data confirmed proliferation and viability results of performed 2D culture 
experiments (Figure 13). 
 
 
Figure 19 Lack of Pdpn did not affect BDVII-V5 tumor cell proliferation in the 3D 
organotypic culture. 
Ki67 IHC was performed to evaluate proportion of proliferating BDVII-V5 tumor cells cultured in 
the SCM. Amount of Ki67-positive tumor cells was visually estimated. No difference between 
Pdpn KO- and control (ctrl)-V5 cultures were observed at any time point. N=3 with technical 
triplicates. Representative bright-field images are depicted. Scale bar 100 µm; zoom 50 µm, 
image quality was optimized by adjustment of brightness, contrast and gamma. W week. 
 
  
                                               
2
 This experiment was performed by Jakob Schneider as part of his Bachelor thesis supervised by myself. 
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3.2.3.4.3 Tumor Cell Invasion Was Epithelial-Mesenchymal Transition-Independent in 3D 
Context 
In collective tumor cell invasion epithelial-mesenchymal transition (EMT) was reported to 
be either absent or partial (reviewed in Friedl et al. (2012)). In EMT-independent invasion, 
tumor cells maintain their epithelial marker expression (e.g. keratins or E-cadherin), 
whereas tumor cells undergoing partial EMT gain mesenchymal marker expression such 
as N-cadherin or vimentin additionally to epithelial features. Descriptive analysis of cSCC 
patients’ material showed that PDPN-positive cancer cells invaded collectively without 
undergoing EMT (Hesse et al. 2016). However, whether differentiated cSCC can also 
represent a partial phenotype has not been shown yet. Hence, I explored E-cadherin as 
well as vimentin expression levels in invading BDVII-V5 tumor cells cultured in the SCM.  
IF staining demonstrated that all undifferentiated tumor cells expressed E-cadherin 
independent of PDPN expression or invasive behavior at any analyzed time point 
(Figure 20). Vimentin was detected in hDFs in the dermal compartment, but not in any 
tumor cell.  
These results underscored that PDPN-driven cSCC invasion in the utilized 3D organotypic 
SCM emerged in the absence of EMT. 
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Figure 20 EMT-independent invasion upon Pdpn deletion in murine cSCC cells in 3D 
context. 
IF staining revealed that E-cadherin, but no vimentin, was expressed by PDPN-positive and 
-negative tumor cells. High levels of vimentin were observed in hDF. Hoechst was used for 
nuclear counterstain. Dashed line represents BM. N=3 with technical triplicates. Representative 
images are displayed. Scale bar 100 µm, image quality was optimized by adjustment of 
brightness, contrast and gamma. W weeks. 
 
3.2.3.5 Podoplanin Loss Does Not Impair Downstream Signaling 
Tumor cell invasion in PDPN-overexpressing cells was shown to be mediated by ERM 
proteins (Scholl et al. 1999, Martin-Villar et al. 2006, Wicki et al. 2006). The activation of 
these proteins result in cytoskeleton rearrangements and hence, in increased migration 
and invasion (Martin-Villar et al. 2006, Wicki et al. 2006). Consequently, the recruitment of 
ezrin, which is mainly expressed in epithelial cells, was examined since I showed that the 
loss of Pdpn in murine cSCC cells diminished tumor cell invasion (reviewed in Fehon et 
al. (2010)). To assess the subcellular localization of ezrin, the filament K5 was additionally 
visualized. 
Confocal microscopy of 2D-cultured Pdpn-proficient and -deficient BDVII-V5 cells revealed 
that K5 filaments were expressed throughout the cell defining, amongst others, cell shape 
(Figure 21 A). Ezrin expression was enhanced close to the plasma membrane. However, 
no differential recruitment of ezrin to the plasma membrane was observed in Pdpn KO- 
and control-V5 cells.  
Nevertheless, I wondered whether the cytoskeleton was differential modulated ezrin-
independently in PDPN-positive tumor cells leading to enhanced invasion. The myosin 
light chain 2 (MLC2) is responsible for actin contraction among other effectors (Wyckoff et 
al. 2006). For activation, MLC2 gets phosphorylated (P-MLC2) by MLC kinase and 
dephosphorylated by myosin phosphatase (MP) leading to inactivation (Totsukawa et al. 
2004). MP is inactivated by ROCK and thus, P-MLC2 remains active resulting in enhanced 
cell migration (Fukata et al. 2001). To test whether the cytoskeleton was rearranged in 
cSCC tumor cells in a PDPN-dependent manner, P-MLC2 expression was examined in 
BDVII-V5 tumor cells cultured in monolayer culture. E-cadherin expressed was detected 
to visualize the plasma membrane.  
P-MLC2 was detected as dotted signal in tumor cells (Figure 21 B). Visual assessment 
indicated similar P-MLC2 expression in Pdpn KO compared to control cells.  
These findings demonstrated that the PDPN downstream activation of ezrin and 
consequent cytoskeleton rearrangements were not differentially regulated in 2D-cultured 
Pdpn KO cells.  
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Figure 21 Neither ezrin recruitment nor cytoskeleton modulation were affected by Pdpn 
deletion. 
A) IF assessment of ezrin in monolayer cultured control (ctrl)- and KO-V5 cells revealed no 
differential recruitment of ezrin to the plasma membrane. K5 was used as marker for the 
cytoskeleton. B) Similar P-MLC2 was detected in control-V5 and KO-V5 cancer cells. E-cadherin 
stained the plasma membrane. N=1 with 10 images per condition. Nuclei were stained with 
Hoechst. Representative images are displayed. Scale bar 20 µm, image quality was optimized by 
adjustment of brightness, contrast and gamma. 
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3.2.4 Generation of Cas9-Deficient mCherry-Labeled Control and 
Podoplanin-Compromised BDVII Cells 
The abrogation of Pdpn in the murine BDVII-V5 cells displayed a significant reduction in 
transmigration and invasion in vitro. The BDVII-V5 cells express constantly the Cas9 
protein as they were generated using lentiviral transduction (Figure 9 B). Hence, re-
introducing PDPN WT or mutant constructs (e.g. CLEC-2- or ERM-binding mutants) to 
study the underlying molecular mechanisms would result in the deletion of the re-
introduced Pdpn by the constant expression of the Cas9-gRNA-complex. Thus, the Pdpn 
construct for re-expressing PDPN needs to be modified in order to prevent Cas9-mediated 
cutting. The gRNA and the protospacer adjacent motif (PAM) are mediating Cas9 binding 
(Pyzocha et al. 2014, Sternberg et al. 2014). Since the used gRNA is targeting the coding 
region in exon 1 of Pdpn, any amino acid exchange in this region of the Pdpn sequence 
needs to be omitted. The PAM sequence is located directly upstream of the gRNA binding 
site. Unfortunately, this sequence is a Tryptophan which has a unique codon. Thus, no 
silent mutation can be introduced in the Pdpn sequence and whether the special indole 
ring of Tryptophan is involved in gene expression was not reported. However, in order to 
maintain PDPN functionality and to perform mechanistical studies in the future by re-
introducing a WT or mutant form of PDPN, new Pdpn KO and control cells lacking 
continuous Cas9 expression were required. This strategic approach was not pursued 
initially as the transfection of the BDVII cell line was rather inefficient. In order to use these 
newly generated cells, the same validation approach as well as transmigration experiment 
were performed.  
 
3.2.4.1 Generation and Validation of mCherry-Labeled Podoplanin Knockout and 
Control BDVII Cells 
To generate mCherry-labeled Pdpn KO and Cas9 control cells, in the first of multiple steps 
(Figure 22), BDVII WT cells were lentivirally transduced with a construct encoding the 
mCherry marker. Subsequent bulk FACSort guaranteed the generation of a pure mCherry-
expressing cell population (WT-mCh). In order to generate transient Cas9-expressing 
Pdpn KO and control cells, the same constructs as employed for the generation of V5-
labeled BDVII cells were transfected into BDVII WT-mCh cells followed by a bulk FACSort 
(section 3.2.2.1).  
Finally, generated BDVII WT-, control- and Pdpn KO-mCh cells were validated on protein 
level to verify PDPN and mCherry marker expression.  
RESULTS 
 
 
81 
 
Figure 22 Establishment of transiently transfected mCherry-labeled WT, control and 
Pdpn KO BDVII cells.  
The mCherry construct was lentivirally transduced into BDVII WT cells with subsequent bulk 
FACSort. WT-mCh cells were transfected with lentiCRISPR/Cas9 constructs generating Cas9 
control (ctrl)- and Pdpn KO-mCh cells. PDPN and marker expression were validated on protein 
level. 
 
IF analysis confirmed that WT- and control-mCh cells expressed PDPN while no PDPN 
staining was observed in Pdpn KO-mCh culture (Figure 23 A). FACS analysis confirmed 
PDPN expression in WT- and control-mCh cells from low to high cell passages (Figure 
23 B and C). Less than 2 % of PDPN-positive cells were detected in the established KO-
mCh culture. That proportion was retained over time until cells reached high passage 
number. FACS analysis of the cells showed additionally that all three sublines expressed 
the introduced mCherry marker. Western blot analysis demonstrated similar PDPN levels 
for WT- and control-mCh cells (Figure 23 D). No PDPN was detected in the KO-mCh 
subline. Importantly, no Cas9 protein expression was detected in control- and KO-mCh 
cells compared to initial lentivirally transduced Cas9- and KO-V5 cells, which expressed 
Cas9. Furthermore, cell morphology was analyzed visually. Bright-field microscopy of 
cultured cells displayed similar cobble-stone-like structure between WT-, control- and 
Pdpn KO-mCh monolayer cultures (Figure 23 E). 
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Figure 23 Evaluation of PDPN and mCherry expression in BDVII cells.  
A) BDVII WT- and control (ctrl)-mCh cells expressed strongly PDPN observed by IF. KO-mCh 
cells did not show any PDPN signal. B) FACS analysis confirmed PDPN-positive population in 
WT- and ctrl-mCh cultures as well as PDPN-negative population in KO-mCh culture. The small 
amount of PDPN-positive cells in KO-mCh culture was retained from early to late passages. 
Moderate to high mCherry levels were expressed by WT-, ctrl- and KO-mCh cells. C) Overview 
of percentage portion in quadrant 1 to 4 (Q1-4) in early and late culture passages. D) Western 
blot analysis confirmed presence or absence of PDPN in WT, ctrl and KO cells either labeled 
with V5 or mCh, respectively. No Cas9 protein was detected in transiently transfected ctrl- and 
KO-mCh sublines compared to transduced V5-cells. E) Bright-field microscopy revealed similar 
morphology of mCh-labeled BDVII sublines. Nuclei were stained with Hoechst. Scale bar 50 µm, 
image quality was optimized by adjustment of brightness, contrast and gamma. 
 
In addition, cell proliferation and viability were examined in BDVII-mCh cells (chapter 
3.2.3.1). Manual cell determination showed that the abrogation of Pdpn did not affect 
proliferation as similar cell numbers were detected for WT-, control- and KO-mCh cells 
(Figure 24 A). Moreover, results of the cell viability test indicated no difference between 
BDVII-mCh sublines (Figure 24 B).  
 
 
Figure 24 Loss of Pdpn had no effect on BDVII-mCh tumor cell proliferation and viability.  
A) Proliferation was examined by manual counting using the Neubauer chamber and trypan 
blue to identify dead cells. B) XTT assay was performed to determine cell viability. Both tests 
were done 24, 48 and 72 h after cell seeding. Cell amount and viability increased over time in 
BDVII-mCh cSCC cells. No difference was obtained comparing KO with control (ctrl) cells. 
Values are plotted as mean and SD of n=3 independent experiments with technical triplicates. 
Unpaired two-tailed Welch’s t test was performed with a 95 % confidence level. N.s. not 
significant. 
 
Taken together, I was able to establish Pdpn KO and control BDVII-mCh cell populations 
via transient transfection, which lack Cas9 expression. 
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3.2.4.2 Podoplanin Deletion Decreases Transmigration in BDVII-mCherry Cells 
The newly generated and validated control- and Pdpn KO-mCh BDVII cells were tested 
for their transmigratory capacity in order to confirm that these sublines show the same 
phenotype as previously generated BVII-V5 cells. Therefore, the BCM assay was 
performed as described (Figure 14 A).  
IF staining of transmigrated cells confirmed strong PDPN expression in control-mCh cells, 
whereas no PDPN-positive KO-mCh cell was detected (Figure 25 A). Pdpn deletion 
resulted in reduced transmigration compared to control-mCh cells (Figure 25 B).  
Thus, Pdpn-proficient and -deficient BDVII-mCh cells, which were generated by transient 
Cas9 expression showed similar results as their BDVII-V5 counterparts. 
 
 
Figure 25 Investigation of the transmigratory potential in Pdpn KO- and control-mCh 
BDVII cells. 
A) Transmigrated control (ctrl)-mCh cells expressed PDPN. No PDPN signal was detected in 
transmigrated KO-mCh cells. B) Transmigration was significantly reduced upon the loss of 
Pdpn. Values are plotted as mean and SD of n=3 independent experiments with technical 
triplicates. 5 fields per technical replicate were analyzed. Unpaired two-tailed Welch’s t test was 
performed with a 95 % confidence level. ** p < 0.01. Scale bar 100 µm, image quality was 
optimized by adjustment of brightness, contrast and gamma. 
 
In summary, the applied LOF approach led to the establishment of two different sets of 
labeled Pdpn KO and control murine BDVII cSCC cells. After successful validation of 
PDPN as well as marker expression level, these sublines were used in functional in vitro 
experiments. The loss of Pdpn in these murine tumor cells, which represent a differentiated 
cSCC morphology, did neither influence proliferation nor cell viability in either monolayer 
or 3D context. Notably, in both established cell sets Pdpn KO resulted in diminished cell 
transmigration. These results were supported by using the most advanced 3D organotypic 
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model system showing that the loss of Pdpn impaired tumor cell invasion into the dermal 
equivalent significantly. The examination of EMT showed neither a loss of the epithelial 
marker E-cadherin nor a gain of the mesenchymal marker vimentin in tumor cells. These 
results indicated a causal relation between PDPN expression and tumor cell invasion in 
an EMT-independent manner. 
 
3.3 Impact of Podoplanin Deletion during Skin Cancer 
Progression in Vivo 
The lack of Pdpn in cSCC cells impaired tumor cell migration and invasion in vitro. 
Together with the performed descriptive analysis of PDPN protein expression in well-
differentiated cSCC patients’ material and additional clinical studies, these results strongly 
supported the previous assumption on a crucial role of PDPN in cSCC carcinogenesis and 
invasive behavior (Vinicius de et al. 2011, Wojciechowska-Zdrojowy et al. 2016). Thus, the 
impact of Pdpn deletion was investigated in an orthotopic mouse model to examine the 
link between PDPN expression and cSCC tumor cell invasion and cancer progression in 
vivo and to complement in vitro experiments. 
I decided to use an intradermal (i.d.) injection approach as developing tumors can be 
investigated in an organ-specific microenvironment reflecting characteristics of both, 
original murine tumors and human physiology. Moreover, injected tumors form and 
progress rather fast and hence, tissue can be analyzed within weeks to months. 
Immunosuppressed patients are at higher risk to develop cSCC (Waldman and Schmults 
2019). Thus, I chose a model system which is mimicking skin carcinogenesis in these 
patients by defining the function of PDPN in the progression of cSCC in T cell-deficient 
nude mice (Rj:NMRI-Foxn1nu/nu).  
Generated Pdpn KO and control BDVII-mCh cSCC cells were injected i.d. into nude mice. 
Two different experimental strategies were pursued: time- and size-matched tumor 
analysis. For the time-matched approach, KO and control tumors were harvested on the 
same day post-injection, when tumor volumes reached around two-thirds of the allowed 
maximum in one group (max. 1.5 cm in diameter). This time point was applied to test 
whether PDPN interferes with cSCC cancer development in general like tumor outgrowth 
and final tumor volume. Further, PDPN-positive and -negative tumors were harvested 
when they reached a volume of approximately 60 mm3 in order to study the influence of 
PDPN at an earlier tumor stage as well as to analyze potential differences in tumor 
characteristics at the same tumor size. In both procedures, tumor growth was monitored 
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regularly (Equation 1). Final tumor volumes were detected more precisely by measuring 
directly all three dimensions before harvesting the tissue (Equation 2). Harvested tumors 
were characterized by indicative histological analysis defining the nature of the tumor. 
Notably, mice were euthanized when termination criteria were reached such as ulcers. 
These animals were excluded from the analysis as well as tumors which showed additional 
skin reactions. 
 
3.3.1. Loss of Podoplanin Results in Smaller Tumor Volumes and Delayed 
Tumor Outgrowth 
During the first injection round, tumor diameter of i.d. injected control-mCh cells reached 
around 9 mm 14 days after injection. Thus, this time point was chosen for the time-matched 
analysis to have sufficient flexibility to include tumors, which might reach the maximal 
tumor volume faster in subsequent injection rounds.  
Tumor development upon injection of BDVII-mCh cells was monitored over time and in 
general, all injected BDVII-mCh sublines formed i.d. tumors (Figure 26 A). Comparing final 
volumes of tumors derived from WT- and control-mCh cells, no difference was observed 
(Figure 26 B). The loss of Pdpn resulted in smaller tumor volumes obtained in the time-
matched analysis (Figure 26 B). Moreover, the size-matched experiment indicated that 
KO-mCh cells reached the required volume of around 60 mm3 on average 1.4 days later 
than control-mCh cells (Figure 26 C and D).  
Independent of PDPN expression, well-differentiated tumors were formed and all tumor 
cells expressed the introduced mCherry marker (Figure 27 A and B). Moreover, small 
groups of tumor cells were observed within the stroma suggesting collective tumor cell 
invasion (Figure 27 B). In order to confirm PDPN protein levels in developed tumors, PDPN 
expression was examined by IF. Co-staining for the epithelial cell marker pan cytokeratin 
(pCK) demonstrated that PDPN was only detected in control-mCh tumors (Figure 27 C). 
No PDPN expression was observed in KO-mCh tumor cells. Independent of PDPN-
expressing cancer cells, a weak PDPN-positive reaction was also detected in tumor 
microenvironment (TME), which were most likely CAFs.  
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Figure 26 Reduced tumor volume and delayed outgrowth of Pdpn KO-mCh tumors. 
A) Tumor volumes were monitored over time in time-matched experiment. WT-mCh n=4, control 
(ctrl)-mCh n=10, KO-mCh n=13. B) Loss of Pdpn resulted in decreased tumor volume in time-
matched analysis. C) Tumor outgrowth was decelerated in Pdpn KO-mCh tumors. N=5. D) Ctrl- 
and KO-mCh tumors were isolated when tumors reached ~60 mm3. Unpaired one-tailed Mann-
Whitney test was performed with a 95 % confidence level for time-matched analysis and unpaired 
two-tailed Welch t test for size-matched experiment. N.s. not significant, * p < 0.05, ** p < 0.01. 
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Figure 27 Orthotopically applied BDVII-mCh cells formed well-differentiated cSCCs.  
A) Well-differentiated tumors were established independent of PDPN expression upon i.d. 
injection. B) Tumor cells expressed mCherry marker. Small groups of tumor cells were detected 
in the stroma. C) Tumors derived from control (ctrl)-mCh cells expressed highly PDPN at the 
invasive front. No PDPN expression was obtained in Pdpn KO-mCh tumors. Additionally, a weak 
PDPN-positive reaction was observed in CAFs independent of PDPN expression of tumor cells 
(arrowheads). Hematoxylin or Hoechst were used to stain nuclei. Representative images are 
depicted. Scale bar A) 1000 µm, B) and C) 100 µm, image quality was optimized by adjustment 
of brightness, contrast and gamma. 
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3.3.2 Diminished Proliferation in Podoplanin-Deficient Tumor Cells 
PDPN-expressing control-mCh cells gave rise to larger tumors at a shorter time compared 
to Pdpn KO-mCh cells. In order to determine whether PDPN expression affected tumor 
cell proliferation or apoptosis in vivo, different histological stainings were performed.  
Comparing control- and KO-mCh tumors no difference was observed in apoptosis as 
examined visually by cleaved caspase 3 expression (Figure 28 A). Hardly any tumor cell 
showed a positive staining indicating that the vast majority of tumor cells were in a viable 
state. Hence, Ki67 was analyzed, which is expressed in all phases of cycling cells. Visual 
examination showed similar expression of Ki67 in nearly all cells of PDPN-positive and -
negative tumors supporting that almost no tumor cells was apoptotic (Figure 28 B). 
However, using this method no statement can be done about how efficient tumor cells are 
undergoing cell division. To further investigate differential proliferation rate in vivo, BrdU 
was injected intraperitoneally (i.p.) four hours before animals were euthanized. Thereby, 
BrdU was incorporated into DNA during S-phase of cycling cells. Staining of BrdU 
indicated visually a potential difference and therefore, manual counting of regions of 
interests was performed (Figure 28 C). Quantification revealed that less cells incorporated 
BrdU in Pdpn-negative tumors suggesting that PDPN-expressing control tumor cells 
entered S-phase more efficient than Pdpn KO cells (Figure 28 D).  
Taken together, i.d. injection of murine BDVII-mCh cells lacking Pdpn resulted in slower 
cycling tumor cells and hence, in smaller tumors and delayed tumor outgrowth, 
respectively. 
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Figure 28 Pdpn-negative tumor cells entered S-phase less efficient in vivo. 
A) Only single apoptotic tumor cells were detected by cleaved caspase 3 staining. No difference 
was observed between tumors derived from control (ctrl)- or KO-mCh cells. B) Ki67 staining 
revealed that majority of tumor cells was within the cell cycle. Ctrl-mCh n=7 and KO-mCh n=9. 
C) Pdpn KO tumors incorporated less BrdU. D)  Decreased BrdU-positive tumor cells were 
detected in KO tumors. Ctrl-mCh n=3 and Pdpn KO-mCh n=4. Nuclei were counterstained with 
hematoxylin. Representative bright-field images are depicted. Scale bar 50 µm. Unpaired two-
tailed Welch’s t test was performed with a 95 % confidence level. ** p < 0.01. Image quality was 
optimized by adjustment of brightness, contrast and gamma. 
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3.3.3. Reduced Invasion upon Podoplanin Deletion in an Epithelial-
Mesenchymal Transition-Independent Manner 
The expansive growth of PDPN-expressing tumor cells resulted in a larger tumor volume. 
Besides enhanced proliferation, malignant progression of solid cancer such as cSCC is 
also promoted by tumor cells, which are invading locally into the TME without undergoing 
EMT (reviewed in Friedl et al. (2012)). Employing the 3D organotypic SCM, I demonstrated 
that PDPN-positive BDVII-V5 cells invaded more and deeper into the dermal equivalent 
(Figure 18). These data implied a fundamental role of PDPN in tumor cell invasion in vitro. 
Hence, the invasive capacity of Pdpn KO- and control-mCh tumor cells was studied in 
tumor samples. 
Laminin is one major component of the BM and gets lost upon tumor cell invasion (Watt 
2014, Poltavets et al. 2018). Therefore, I performed co-staining of laminin and K14, as 
epithelial cell marker, in order to determine stroma infiltrating tumor cells. Undifferentiated 
tumor cells, either derived from control- or KO-mCh cells, showed K14 expression and 
laminin was detected at the outer edge of the tumor bulk (Figure 29 A). Small groups of 
tumor cells, which were not connected to the bulk and partially lost laminin, were observed 
indicating collective tumor cell invasion.  
For quantitative analysis, images of the tumor margin were analyzed semi-automatically 
utilizing an ImageJ macro. Invading tumor cells were determined as described in the 
following: groups of tumor cells at the tumor edge, which were not connected to the tumor 
bulk, were selected by K14 signal. Laminin coverage at the outer edge of these infiltrative 
buds was detected. K14 areas with laminin coverage below 15 % were defined as invading 
tumor cells. The area of these invading cells was determined according to K14 staining. 
This quantitative analysis demonstrated a trend close to significance that Pdpn abrogation 
reduced the amount of tumor cells invading the stroma (Figure 29 B). 
Examination of the SCM revealed that tumor cells were invading collectively in the 
absence of EMT (Figure 20) and orthotopic injected control- and KO-mCh BDVII cells 
showed small groups of mCherry-positive tumor cells within the stroma indicating 
collective tumor cell invasion (Figure 27 B). Thus, E-cadherin as epithelial and vimentin as 
mesenchymal markers were analyzed assessing EMT. Pdpn-proficient and -deficient 
tumor cells expressed E-cadherin whereas vimentin was detected in fibroblasts 
(Figure 29 C). Only single tumor cells expressed vimentin additionally to E-cadherin 
indicating that these cells underwent partial EMT.  
To sum up, the orthotopic injection mouse model highlighted the significance of PDPN in 
cSCC tumor cell invasion, since less infiltrative tumor cells upon Pdpn loss were observed. 
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Moreover, i.d. tumors derived from either Pdpn-positive or -negative cells established in 
an EMT-independent manner.  
 
 
Figure 29 Lowered tumor cell invasion in an EMT-independent manner upon Pdpn 
deletion.  
A) Undifferentiated control (ctrl)- and KO-mCh tumor cells expressed K14. Small groups of 
tumor cells invaded into the stroma and lost laminin expression partially. Dashed line represents 
BM of tumor bulk. B) Quantitative analysis of laminin-K14-co-staining revealed that KO-mCh 
tumor cells tended to infiltrate less into the stroma. Values are plotted as cumulative sum and 
SD of n=3 tumors derived from either ctrl- or KO-mCh cells. For each tumor, 3 non-consecutive 
sections with 5 fields per section were analyzed. Unpaired two-tailed Welch’s t test was 
performed with a 95 % confidence level. C) IF staining revealed that independent of PDPN 
expression tumor cells expressed E-cadherin, but no vimentin. Only single tumor cells showed 
partial EMT by expressing both, vimentin and E-cadherin (arrowhead). High levels of vimentin 
were observed in fibroblasts. Nuclei were stained with Hoechst. Representative images are 
displayed. Scale bar A) 50 µm and C) 100 µm, image quality was optimized by adjustment of 
brightness, contrast and gamma.  
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In conclusion, Pdpn KO and control murine BDVII cSCC cells formed well-differentiated 
tumors upon orthotopic injection into nude mice. Histological analysis revealed that stromal 
cells also showed a PDPN-positive reaction independent of the PDPN status of injected 
tumor cells. Consequently, the chosen i.d. injection model recapitulated characteristics of 
human patient material (Figure 7). Importantly, tumor cells lacking Pdpn entered S-phase 
less efficiently resulting in diminished tumor volume and decelerated tumor outgrowth. 
Furthermore, small groups of either PDPN-positive or -negative tumor cells infiltrated into 
the stroma in an EMT-independent manner. Notably, reduced infiltrative capacity was 
observed upon Pdpn KO. Thus, this employed in vivo approach underscored the 
importance of PDPN in cSCC carcinogenesis since the deletion of this glycoprotein 
impaired both, tumor growth and tumor cell invasion.  
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4 DISCUSSION 
Multiple studies have revealed that the expression of podoplanin (PDPN) is associated 
with tumor progression in solid cancer derived from human patients or mouse models 
(Schacht et al. 2005, Durchdewald et al. 2008, Cueni et al. 2010, Honma et al. 2012, Kunita 
et al. 2018). 90 % of cutaneous squamous cell carcinoma (cSCC) strongly express PDPN 
in tumor cells particularly at the leading edge of the tumor as well as in cancer-associated 
fibroblasts (CAFs; Wicki and Christofori (2007), Honma et al. (2012), Wojciechowska-
Zdrojowy et al. (2016)). This enhanced PDPN expression correlates with poor patient 
survival and results in increased metastasis as demonstrated by descriptive clinical 
investigations (Toll et al. 2012, Vinicius de et al. 2011, Wojciechowska-Zdrojowy et al. 
2016). Mechanistically, strong PDPN expression was shown to increase migration and 
invasion in gain-of-function (GOF) in vitro experiments (Scholl et al. 1999, Martin-Villar et 
al. 2006, Wicki et al. 2006). However, the exact mechanism seems to be contextual since 
different modes of action were reported in tumorigenic and non-tumorigenic epithelial cells. 
Thus, only little is known about the role of PDPN in skin cancer development. The fact that 
the incidence of cSCC is increasing as well as late stages of this cancer entity are difficult 
to treat highlights that there is a substantial need for novel treatment options.  
In this study, I show for the first time that PDPN drives proliferation and collective invasion 
of well-differentiated cSCC cancer cells. Subsequent to the detection of PDPN in cancer 
cells at the invasive front in differentiated cSCC, the causality of PDPN expression on 
cSCC progression was addressed in functional assays by using the CRISPR/Cas9 
technology. The employed orthotopic injection model showed that the tumor volume as 
well as tumor outgrowth were significantly reduced or delayed, respectively, in tumors 
derived from Pdpn-deficient cells that were due to diminished cancer cell proliferation. 
Moreover, functional in vitro and in vivo experiments demonstrated that the invasive 
capacity was impaired and moreover, independent of epithelial-mesenchymal transition 
(EMT) upon the loss of Pdpn in murine cSCC cells. These findings underscore the 
importance of PDPN in the progression of differentiated cSCC by promoting cancer cell 
proliferation and invasion. 
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4.1 Differentiated Cutaneous Squamous Cell Carcinoma 
Express Podoplanin 
The expression of PDPN has been described in various human tumors such as cervix, 
breast, head and neck as well as cSCC (Martin-Villar et al. 2005, Schacht et al. 2005, 
Vinicius de et al. 2011, Honma et al. 2012, Toll et al. 2012, Lan et al. 2014, Hesse et al. 
2016, Kunita et al. 2018). Independent of the tumor entity, PDPN expression was localized 
in tumor cells at the invasive front suggesting that this glycoprotein acts as a driver of 
invasiveness and cancer progression. Two descriptive studies reported that PDPN 
expression correlated negatively with differentiation, in particular, well-differentiated 
tumors showed only low levels of PDPN if at all, whereas poorly-differentiated expressed 
high levels of this glycoprotein (Schacht et al. 2005, Vinicius de et al. 2011). In this thesis, 
I analyzed one moderately- and five well-differentiated human cSCCs. Examined tumors 
expressed PDPN in tumor cells at the tumor-stroma border, which is in contrast to 
published data (Schacht et al. 2005, Vinicius de et al. 2011). Previously, PDPN was 
reported to be upregulated in basal keratinocytes around the wound margins (Baars et al. 
2015). By using an in vivo loss-of-function (LOF) approach, in which Pdpn is deleted 
specifically in Keratin 14 (K14)-expressing keratinocytes, the authors showed that the 
deficiency of Pdpn was dispensable for re-epithelialization during wound healing and, 
notably, for cornification (Baars et al. 2015). Thus, there is no causal link between PDPN 
expression and keratinocyte or epidermal tumor differentiation, respectively. Moreover, I 
observed PDPN expression in the stroma pointing to PDPN-positive CAFs, which was also 
reported by Wojciechowska and co-workers (Wojciechowska-Zdrojowy et al. 2016). 
Consequently, based on these findings, I hypothesized that PDPN plays a major role also 
in differentiated cSCC. In order to define its function, a LOF approach was utilized which 
is discussed in the following chapters.  
 
4.2 Podoplanin Does neither Affect Morphology nor 
Proliferation in Vitro 
Since PDPN is expressed in cSCC at any stage of differentiation according to my results 
and published reports, I selected the two human cSCC cell lines SCL-II and MET-4 as well 
as murine BDVII cells to investigate the role of PDPN in cSCC carcinogenesis (Schacht et 
al. 2005, Vinicius de et al. 2011). SCL-II and MET-4 cells represent undifferentiated tumors 
from different stages, as they were isolated from a facial primary lesion and a lymph node 
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metastasis, respectively (Tilgen et al. 1983, Popp et al. 2000, Proby et al. 2000). The 
murine BDVII cell line was established from a well-differentiated murine tumor that 
developed upon 7,12-Dimethylbenz-[a]-anthracene (DMBA) treatment in the course of a 
chemical carcinogenesis protocol (Fusenig et al. 1978). PDPN knockout (KO) and control 
sublines were established for these three cSCC cell lines using the CRISPR/Cas9 
technology and detection of PDPN protein levels verified successful generation.  
Functional analysis in monolayer culture revealed that the lack of PDPN did neither 
influence morphology nor proliferation in either SCL-II, MET-4 or BDVII tumor cells. 
Previously, only studies with other cell types than cutaneous epithelial cancer cells were 
performed. In vitro cultivation of primary murine Pdpn KO keratinocytes, which were 
generated by an in vivo LOF approach, did not alter proliferation in comparison to Pdpn-
proficient control keratinocytes (Baars et al. 2015). Proliferation was neither influenced in 
non-tumorigenic keratinocytes nor in breast cancer cells upon ectopic overexpression of 
PDPN, which is in agreement with my studies (Scholl et al. 1999, Wicki et al. 2006). 
However, PDPN-dependent proliferation seems to be context-dependent, since orthotopic 
tumor cell injections, which were performed in this study, showed diminished tumor cell 
proliferation, which will be discussed in chapter 4.6.1. 
 
4.3 Transmigration and Invasion Are Diminished in Murine 
Tumor Cells Lacking Podoplanin 
The deficiency of PDPN in human and murine cSCC cells did not impair tumor cell features 
in monolayer culture. Hence, in order to investigate the functional consequences of PDPN 
on migration and invasion, I used two different more advanced in vitro procedures. First, 
established human and murine control and PDPN KO cells were applied in the Boyden 
Chamber matrigel (BCM) assay. This method is commonly performed to assess the 
transmigratory capacity of cells in vitro since it is quick, quantitative and reproducible 
(Bloomfield et al. 2001, Kleinman and Jacob 2001). In this experimental approach, cells 
are seeded on top of matrigel-coated filters. Cells transmigrate through the matrigel along 
a serum-gradient during a cell line-specific incubation time and the number of 
transmigrated cells can be quantified. Despite giving insights into the transmigratory 
potential of intrinsic tumor cell factors, the BCM assay, however, lacks the complexity of a 
tissue context, which is present in vivo. Hence, to further complement the understanding 
of tumor cell invasion in vitro, the 3D organotypic skin cancer model (SCM) was used as 
the second method (Berning et al. 2015). In comparison to traditional systems, the SCM 
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is more elaborated. Briefly, epithelial cancer cells grow air-exposed on top of a fibroblast 
feeder layer consisting of primary dermal fibroblasts that produce matrix themselves. Thus, 
this organotypic system allows analyzing the cell behavior in a more appropriate 
environment, since this model mimics the epidermal-dermal context. 
Functional analysis of human and murine cSCC cells revealed that the transmigratory and 
invasive potential differed in both the BCM assay as well as in the SCM upon PDPN 
deletion. SCL-II and MET-4 cells lacking PDPN showed similar transmigratory and 
invasive behavior compared to control cells. Strikingly, the loss of Pdpn in murine BDVII 
cells resulted in decreased transmigration in the BCM as well as in reduced invasive area 
and covered invaded distance in the SCM. The different transmigratory and invasive 
behavior of human and murine cell lines might be due to various reasons. The level of 
PDPN expression is only moderate in SCL-II and MET-4 cells, whereas all murine BDVII 
cells strongly express PDPN. Hence, the delta of PDPN expression between KO and 
control cells originated from SCL-II and MET-4 cell lines might not be high enough to be 
able to detect an effect. Other aspects, which could explain the unaltered migration of 
human cells upon PDPN loss, might be due to their tumor origin and morphology. SCL-II 
and MET-4 cell lines were established from human undifferentiated primary tumor lesion 
or lymph node metastasis, respectively, whereas BDVII cells were isolated from a murine 
well-differentiated primary tumor, which emerged upon a chemical tumorigenesis protocol 
(Fusenig et al. 1978, Tilgen et al. 1983, Popp et al. 2000, Proby et al. 2000). Hence, 
various genes are differentially mutated in these cell lines. For instance, BDVII cells harbor 
a mutant form of the Ha-Ras proto-oncogene and SCL-II a mutant form of the tumor 
suppressor TRP53, whereas both genes are not mutated in MET-4 cells (Fusenig et al. 
1978, Tilgen et al. 1983, Popp et al. 2000, Proby et al. 2000). In order to investigate the 
importance of PDPN in cSCC progression in this study, these cell lines were selected 
particularly because of these differences to extend the spectrum to a variety of cSCCs 
representing different tumor characteristics. However, additional molecular alterations 
favoring migration and invasion were probably gained in the course of cancer development 
in individual original human tumors. Thus, it cannot be excluded that known gene 
mutations as well as additional alterations might trigger compensatory responses upon 
PDPN loss. Baars and colleagues demonstrated that the depletion of Pdpn in basal 
keratinocytes did neither impair skin development nor wound healing assuming that other 
yet undefined molecular mechanisms were balancing the loss of Pdpn (Baars et al. 2015). 
Potential candidates could be other proteins with similar location and function such as 
CD44. CD44 like PDPN links the plasma membrane to the cytoskeleton via the interaction 
with the ezrin, radaxin and moesin (ERM) protein family resulting in increased invasion 
(Hirao et al. 1996, Yonemura et al. 1998, Isacke and Yarwood 2002). Since more human 
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cSCC cell lines are available that are used in skin cancer research (chapter 1.2.1), the 
impact of PDPN should be analyzed in these cell lines additionally. These further 
investigations would complement the understanding of PDPN function in the human cell 
system and potential species-specific alterations that were observed in this study could be 
excluded.  
Thus, I used Pdpn KO and control BDVII cells for further studies of PDPN’s role in 
differentiated cSCC. My findings of the murine BDVII cell behavior in dependence of PDPN 
are in line with published data. Ectopic expression of human PDPN in non-tumorigenic 
Madin-Darby canine kidney (MDCK) cells or the MCF7 breast cancer cell line resulted in 
enhanced migration assessed by the BCM assay (Martin-Villar et al. 2006, Wicki et al. 
2006). Invasively growing BDVII cells in the SCM showed cornified pearls within the 
dermal compartment. On the one hand, this characteristic reflects the morphology of 
original DMBA-induced tumors (Fusenig et al. 1978). On the other hand, this feature 
mimics 90 % of human cSCC that display a well-differentiated morphology (Stenman et al. 
2018). Thus, the BDVII cell line used in the SCM presents a valid model system that 
recapitulates PDPN-dependent invasion in cSCC.  
Subsequently, a more detailed analysis of 3D-cultured BDVII cells was performed to 
determine the invasive character. The proliferative behavior of organotypically cultured 
cells was examined since expansive cancer cell growth results in passive migration, which 
could be one reason for enhanced invasiveness in PDPN-positive BDVII cells. Ki67 
staining demonstrated that proliferative activity was similar in Pdpn KO and control cells. 
These findings supported 2D in vitro analysis discussed in chapter 4.2. No reports 
examining PDPN-dependent proliferation in 3D are available and reported in vivo data will 
be discussed in the corresponding chapter (4.6.1). 
Moreover, I observed small groups of invading cells in Pdpn KO and control cultures 
suggesting collective tumor cell invasion. So far, collective invasion of differentiated 
cutaneous epithelial tumors was associated with partial EMT or absence of EMT (Friedl et 
al. 2012, Lan et al. 2014, Hesse et al. 2016). Detection of the epithelial marker E-cadherin 
and the mesenchymal marker vimentin revealed that Pdpn KO and control BDVII cells 
invaded in the absence of EMT, which corresponds to clinical patient data (Lan et al. 2014, 
Hesse et al. 2016). The impact of PDPN on EMT was so far either analyzed in 2D culture 
systems or in vivo, which will discussed in chapter 4.6.2. Previous 2D in vitro investigations 
utilized PDPN GOF approaches in different cell lines. Scholl and colleagues examined 
murine non-tumorigenic keratinocytes and showed that the expression of E-cadherin as 
well as K14 were lost and vimentin was enhanced upon murine Pdpn overexpression 
(Scholl et al. 2000). Similar morphological changes were observed in MDCK cells 
overexpressing human PDPN, where E-cadherin expression was reduced, while N-
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cadherin was increased, indicating these cells underwent the so-called cadherin switch 
(Martin-Villar et al. 2006, Fernandez-Munoz et al. 2011). Moreover, the epithelial keratin 
filament 8 was also decreased and vimentin expression was enhanced upon PDPN 
overexpression indicating that ectopic PDPN overexpression triggered EMT (Martin-Villar 
et al. 2006, Fernandez-Munoz et al. 2011). In contrast to these studies, ectopic PDPN 
overexpression did not affect E-cadherin levels in MCF7 breast cancer cells and also not 
EMT (Wicki et al. 2006). In conclusion, the abrogation of epithelial markers and the gain 
of mesenchymal protein expression upon PDPN overexpression were shown to be 
context-dependent in monolayer culture.  
 
4.4 Intracellular Podoplanin Signaling via Ezrin Is Not Influenced 
in Monolayer Culture 
The invasive capacity of PDPN-expressing cells was reported to be mediated through the 
interaction with the ERM protein family (Scholl et al. 1999, Martin-Villar et al. 2006, Wicki 
et al. 2006). ERM proteins are activated via phosphorylation mediated by kinases including 
Rho GTPases (RhoA, Rac1 and Cdc42) at the plasma membrane followed by binding to 
PDPN resulting in actin cytoskeleton remodeling and thus, migration and invasion (Scholl 
et al. 1999, Bretscher et al. 2002, Martin-Villar et al. 2006). Confocal microscopy of 2D-
cultured BDVII cSCC cells revealed that PDPN-positive tumor cells recruited ezrin to the 
plasma membrane. Subsequently, phosphorylated myosin light chain 2 (P-MLC2) was 
expressed indicating induced cytoskeleton rearrangements. However, the deletion of 
Pdpn did not abrogate ezrin translocation and a similar activity of P-MLC2 was observed. 
Previously, ectopic overexpression of PDPN in MDCK cells resulted in PDPN-ERM-
mediated RhoA activation and enhanced invasiveness in the presence of EMT in vitro 
(Martin-Villar et al. 2006). However, a similar in vitro experimental approach ectopically 
overexpressing PDPN in MCF7 cells demonstrated ezrin recruitment and EMT-
independent invasion without the activation of Rho GTPases (Wicki et al. 2006). 
Interestingly, PDPN-expressing B16.F10 melanoma cells recruited ERM, which was 
abolished upon Pdpn knockdown (KD; Pedro and Shields (2018)). Moreover, the authors 
identified an alternative mechanism without activation of Rac1 or Cdc42 but including 
PAK1-RhoA. Altogether, this suggests a cell context-dependent regulation of ERM 
proteins and Rho GTPases. Therefore, further examination, especially in a 3D context, is 
required in order to decipher the underlying mechanism of PDPN-induced invasion in 
cSCC in vitro. Descriptive analysis by using immunostainings of SCM or tumor sections 
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might be a possibility. However, proper determination of subcellular ezrin localization could 
be difficult due to the close cellular interaction and potential overlap of individual cells 
within tissues. Martín-Villar and co-workers ectopically expressed PDPN in which the 
cytoplasmic tail was deleted or the ERM-binding site was mutated and showed that the 
modification of the intracellular (IC) PDPN domain diminished ezrin recruitment (Martin-
Villar et al. 2006). Hence, the utilization of a Pdpn mutant lacking the ERM binding site 
represents the most appropriate approach. 
 
4.5 Orthotopic Injection Mouse Model Recapitulates Well-
Differentiated Human Cutaneous Squamous Cell Carcinoma 
Although more complex in vitro model systems like the SCM allow the examination of 
migratory and invasive behavior of cancer cells, they still lack the complexity of whole 
tissues and organisms. Consequently, an in vivo mouse model is required to decipher all 
factors of carcinogenesis like tumor growth or interaction of tumor cells with stromal cells 
in dependency of PDPN. Since organ transplant recipients and other immunosuppressed 
patients are at higher risk to develop cSCC, I decided to study the role of PDPN in cSCC 
progression in an orthotopic model using athymic nude mice that lack T cells (Stenman et 
al. 2018, Waldman and Schmults 2019). Nevertheless, it is noteworthy to mention that the 
incidence in immunocompetent patients is increasing due to cumulative sun exposure, for 
instance. Thus, the function of PDPN in this patient cohort should be considered in different 
model systems additionally such as (i) orthotopic injections into immunocompetent mice 
or (ii) genetic engineered mouse models (GEMMs). In the later model system, mice, which 
lack Pdpn specifically in keratinocytes by using, for instance, a K14-Cre recombinase, can 
be utilized. Since PDPN is not tumorigenic autonomously, this GEMM needs to be 
combined with the multistage DMBA/12-O-tetradecanoylphorbol-13-acetate (TPA) 
carcinogenesis protocol (explained in detail in section 1.3.2). Durchdewald and co-workers 
treated the back skin of wild-type (WT) mice with the tumor promoter TPA and established 
papilloma (PAP), which can be defined as a potential pre-malignant lesion of cSCC, 
showed a PDPN upregulation in tumor cells at the invasive front (Durchdewald et al. 2008). 
Consequently, this in vivo approach would represent an appropriate model to characterize 
the impact of PDPN. However, in order to investigate cSCC carcinogenesis, the additional 
tumor initiator DMBA needs to be applied before TPA treatment so that initially formed 
PAP transform to cSCCs over time. In the research group of Prof. Dr. Peter Angel, Pdpn 
floxed as well as K14-Cre mice were established in the mouse strain C57BL/6 (Baars et 
DISCUSSION 
 
 
104 
al. 2015). Unfortunately, this mouse strain is highly resistant to the chemical-based 
protocol resulting in low tumor incidences and multiplicities compared to a susceptible 
strain like 129/SvEv (Reiners and Singh 1997, Yamakage et al. 2000, Gebhardt et al. 
2008). Consequently, C57BL/6 Pdpn floxed and K14-Cre mice would have needed to be 
backcrossed into the DMBA/TPA-sensitive mouse strain 129/SvEv. Successful 
backcrossing requires at least ten generations resulting in a minimum of approximately 
one and a half years before starting the actual experiment, which would have been beyond 
the scope of this study.  
Thus, in this dissertation, I focused on the impact of PDPN in cSCC tumorigenesis in 
immunosuppressed patients. Therefore, labeled Pdpn KO and control murine BDVII cells 
were injected i.d. into nude mice that lack T cells. Established tumors displayed a well-
differentiated morphology upon i.d. injection of both Pdpn-proficient and -deficient BDVII 
cells. Moreover, tumor cells derived from control cells strongly expressed PDPN at the 
tumor-stroma border. Stromal cells, most likely CAFs, showed a PDPN-positive reaction 
as well, in tumors derived from control and Pdpn KO cells. Thus, this model is suitable to 
study the impact of PDPN in cSCC progression, since formed tumors recapitulate the 
human situation (Vinicius de et al. 2011, Toll et al. 2012, Lan et al. 2014, Hesse et al. 
2016, Wojciechowska-Zdrojowy et al. 2016).  
 
4.6 Deletion of Podoplanin Results in Smaller Tumors and 
Delayed Tumor Outgrowth 
Time- and size-matched analysis of i.d. injected control and Pdpn KO cancer cells 
revealed that the abrogation of Pdpn resulted in smaller tumors and delayed outgrowth. 
These findings support the proposed function of PDPN in cSCC, as clinical data reported 
a correlation of PDPN-expressing tumor cells and poor patient survival (Vinicius de et al. 
2011). An in vivo study using short hairpin (sh) RNA-mediated PDPN KD in the human 
vulva SCC cell line A431 demonstrated that tumor volume was reduced upon i.d. injection 
into T cell-deficient BALB/c nude mice (Kunita et al. 2018). Wicki and colleagues employed 
a transgenic pancreas mouse model resulting in PDPN overexpression in insulin-
producing ȕ-cells and showed that the overexpression increased pancreatic tumor 
incidence as well as malignancy (Wicki et al. 2006). In contrast to these studies, primary 
tumor growth of breast carcinoma xenografts was reduced upon orthotopic injection into 
the mammary fatpad of MCF7 cells that ectopically overexpressed PDPN (Cueni et al. 
2010). Interestingly, in PDPN-expressing breast cancer xenografts, the number of lymph 
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vessels and lymph node metastasis was increased. These data indicate that, depending 
on the context, PDPN expression cannot only affect primary tumor growth but also drives 
tumor malignancy by increasing the amount of metastasis. Thus, my findings together with 
published reports underline the crucial role of PDPN in epithelial tumors.  
 
4.6.1 Podoplanin Abrogation Impaired Proliferation in Vivo 
To elucidate the diminished tumor volume and delayed outgrowth in PDPN-negative 
tumors, proliferation and apoptosis in tumor cells were examined in vivo. Almost all PDPN-
positive and -negative tumor cells were proliferating and not apoptotic, as assessed by 
presence of Ki67 and absence of cleaved caspase-3 expression, respectively. Thus, these 
results supported in vitro data. However, Ki67 is expressed in all phases of the cell cycle. 
In order to get a more detailed insight, BrdU incorporation upon intraperitoneal injection 
was additionally determined, since BrdU labels only cells that enter S-phase after injection 
until mice are sacrificed (~ 4 hours). Statistical analysis revealed that BrdU incorporated 
less in Pdpn KO compared to control tumors, indicating less efficient entry into S-phase 
upon Pdpn loss and thus, slower cycling cells and reduced proliferation. Consequently, 
smaller tumor volume and delayed tumor outgrowth can be explained by decreased tumor 
cell proliferation upon Pdpn deletion. In previous studies, the in vivo GOF of PDPN in 
pancreatic insulin-producing ȕ-cells did neither affect proliferation nor apoptosis, as 
examined by BrdU and TUNEL assay, respectively (Wicki et al. 2006). Contrary in the lung 
increased proliferation in type I alveolar cells lacking Pdpn was detected using proliferating 
cell nuclear antigen that is expressed in the nuclei of cells during S-phase (Ramirez et al. 
2003). These converse findings as well as my results observed in monolayer and 3D 
culture systems (chapter 4.2 and 4.3) suggest that the impact of PDPN on proliferation 
depends on the cellular context. Thus, cell-autonomous pathways that induce proliferation 
could be excluded since no difference was observed in 2D-cultured cells. In the 
organotypic co-culture system, soluble factors secreted by fibroblasts might have an 
impact on tumor cell proliferation; however, BrdU labeling should be performed to get a 
more detailed insight on whether the efficiency of S-phase entry is impaired upon Pdpn 
loss in 3D context. Altogether, the findings of the in vivo model highlighted that PDPN-
dependent factors, which are most probably secreted by stromal cells or induced in tumor 
cells upon the contact with cells of the tumor microenvironment (TME), have an impact on 
cancer cell proliferation.  
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4.6.2 Loss of Podoplanin Reduces Invasiveness in an Epithelial-
Mesenchymal Transition-Independent Manner 
Since I observed an invasive phenotype upon the deletion of Pdpn in vitro, I wondered 
whether tumor cells lacking Pdpn showed reduced invasion in vivo as well. Invading tumor 
cells can be defined according to the breakdown of the basement membrane (BM; 
Spaderna et al. (2006), Watt (2014)). Laminin is one component of BM, which is expressed 
by fibroblasts and keratinocytes or tumor cells, respectively (Simpson et al. 2011, Watt 
2014). Therefore, I detected laminin in combination with K14, which marked basal tumor 
cells. Quantitative analysis showed a tendency of less invaded tumor cells in Pdpn KO 
tumors, which was, however, not statistically significant. This effect might become 
significant by increasing sample size since only a small number with three tumors each 
was analyzed with high variation between samples. Kunita and co-workers injected vulva 
SCC cells i.d. into nude mice, which resulted in decreased tumor cell invasion upon 
shRNA-mediated PDPN KD (Kunita et al. 2018). They determined invasion according to 
the circularity of the tumor on hematoxylin and eosin-stained sections. Based on my own 
experience, i.d. injected tumors can display different shapes from circular via elliptical to 
even more elongated. Therefore, I suggest using the examination of laminin in combination 
with K14 as performed in my studies (Spaderna et al. 2006). Moreover, I observed that the 
majority of invading sheets as well as the tumor bulk of control and Pdpn KO tumors did 
not undergo EMT as tumor cells still expressed E-cadherin and expression of vimentin 
was not gained. Noteworthy, some single cells at the leading edge co-expressed E-
cadherin and vimentin indicating partial EMT. Performing exogenous PDPN 
overexpression studies, it was shown previously that PDPN resulted in enhanced invasion 
in an EMT-independent manner in a pancreas in vivo model (Wicki et al. 2006). Clinically, 
PDPN expression was associated with EMT-dependent and -independent invasiveness. 
E-cadherin expression was attenuated in poorly differentiated cSCC, whereas 
membranous expression was reported in well-differentiated tumors, which was linked to 
collective cancer invasion (Lan et al. 2014, Hesse et al. 2016). Furthermore, another study 
demonstrated partial downregulation of E-cadherin at the invasive front, whereas the EMT-
associated transcription factor twist as well as vimentin were upregulated (Toll et al. 2013). 
The descriptive analysis of human SCC of different entities showed that PDPN and E-
cadherin were co-expressed and detected an enlarged invading tumor front indicating 
collective invasion according to Friedl and colleagues (Wicki et al. 2006, Friedl et al. 2012). 
Thus, in agreement with literature, in my studies PDPN-positive and -negative cSCC cells 
invaded collectively without driving an EMT-like behavior, whereas invasiveness was 
impaired in Pdpn KO tumors.  
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4.7 Potential Mechanism of Podoplanin-Dependent Cancer Cell 
Proliferation and Invasion 
The descriptive analysis as well as the application of LOF experiments performed in this 
study conclude that PDPN has a decisive role in cSCC carcinogenesis by driving tumor 
cell proliferation and invasion. Despite that these findings shed some light on the limited 
knowledge of the molecular basis of cSCC, additional investigations are needed to explore 
the underlying mechanism of PDPN-dependent cSCC progression to develop novel 
potential treatment options. 
Since proliferation and invasion are distinct hallmarks of cancer, this raises the question 
of whether there is one or multiple underlying signaling pathways. The transcriptional 
regulation of PDPN was reported to be controlled by various context-specific signaling 
pathways and transcription factors in non-tumorigenic cells as well as in in vivo models (Li 
et al. 2015, Renart et al. 2015, Kunita et al. 2018, Quintanilla et al. 2019). So far, several 
signaling pathways have been proposed in combination with PDPN, however, these 
investigations focused on SCC or other cellular model systems different from cSCC.  
Kunita and co-workers utilized a human papilloma virus-driven mouse model in which the 
viral oncogenes E6 and E7 are expressed under the control of K14-promoter in 
immunocompetent FVB/n mice resulting in the development of cervix SCC upon additional 
treatment with estradiol (Kunita et al. 2018). Gene expression profiling of established 
cervix SCCs as well as additional in vitro and in vivo experiments using various SCC cell 
lines revealed that PDPN upregulation was accompanied by enhanced type-I interferon 
(IFN) as well as cytokine-mediated signaling pathways in tumor cells. The authors 
suggested tumor-infiltrating immune cells secrete multiple factors such as IFN-Ȗ, 
transforming growth factor beta (TGF-ȕ) and interleukin (IL)-6 resulting in the activation of 
various signaling pathways in tumor cells like STAT1 or SMAD-proteins besides PDPN. 
Moreover, the shRNA-mediated KD of PDPN or STAT1 diminished tumor volume and 
invasion in BALB/c nude mice. However, analyzed SCC cells responded differently upon 
cytokine and/or IFN treatment implying that the impact of PDPN in cancer progression 
seems to be strongly contextual. Although these authors suggest that SMAD-dependent 
TGF-ȕ signaling is involved in tumor vulva SCC progression, in cSCC a contradictory role 
of SMAD-dependent TGF-ȕ signaling was described. Frequent mutations in the TGF-ȕ 
receptors or diminished expression of SMAD proteins have been reported suggesting a 
tumor suppressive function of TGF-ȕ in this skin cancer entity (Hoot et al. 2008, Pickering 
et al. 2014). Moreover, Rose and co-workers revealed that cSCC progression is 
associated with the abrogation of canonical TGF-ȕ signaling pathway (Rose et al. 2018).  
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Notably, TGF-ȕ can also trigger other non-SMAD pathways and downstream targets such 
as PI3K or MAPK resulting in enhanced proliferation and invasion (reviewed in Akhurst 
(2017)). This non-canonical TGF-ȕ signaling has been already associated with PDPN-
dependent malignant SCC progression. Li and colleagues demonstrated in oral SCC 
(OSCC) that PDPN was upregulated in tumor cells at the invasive front together with the 
Cdc42 GTPase and complementing GOF and LOF in vitro approaches indicated induced 
invasion in a PDPN-Cdc42-dependent manner (Li et al. 2015). Recently, the same authors 
described the underlying mechanism that is based on paracrine PDPN-TGF-ȕ signaling 
(Li et al. 2018). Briefly, PDPN-positive OSCC tumor cells secret TGF-ȕ which activates 
fibroblasts. Consequently, CAFs secrete TGF-ȕ as well that trans-induces epidermal 
growth factor receptor (EGFR) signaling. Subsequently, EGFR activates phosphoinositide 
3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) pathways resulting in 
proliferation and invasion of OSCC cells. This non-canonical TGF-ȕ signal transduction 
might also explain the effect observed in BCM, in which PDPN-positive tumor cells alone 
transmigrated more efficiently through matrigel than their PDPN-negative counterparts 
that indicates a cell-autonomous or paracrine signaling between tumor cells via TGF-ȕ in 
vitro. Noteworthy, non-canonical TGF-ȕ signaling was not reported yet in cSCC 
progression and besides trans-inducing EGFR, TGF-ȕ activates Rho GTPases as well that 
induces cytoskeletal rearrangement and thus, enhanced migration and invasion (Edlund 
et al. 2002). Several reports have shown that PDPN-induced Rho GTPase activity is 
mediated through ERM proteins (Martin-Villar et al. 2006, Wicki et al. 2006, Pedro and 
Shields 2018). However, whether TGF-ȕ modulates the cytoskeleton in an ERM-
dependent or -independent manner was not shown yet.  
Besides IFNs, cytokines or growth factors, proliferation can also be induced by ezrin. 
Previous in vitro studies utilizing epithelial kidney cells demonstrated that ezrin interacted 
with the regulatory subunit of the PI3K resulting in PI3K activation and thus, in activation 
of the PI3K/AKT pathway and proliferation (Gautreau et al. 1999). Chuan and colleagues 
demonstrated that c-Myc enhanced ezrin expression resulting in increased motility of 
human prostate cancer cells in vitro (Chuan et al. 2010). Moreover, they reported a positive 
regulation of c-Myc by ezrin that was mediated by the activation of AKT and 
downregulation the glycogen synthase kinase 3 beta (GSK-γȕ). Notably, proliferation and 
invasion were diminished in dominant negative ezrin variants mutants in vitro. In another 
in vitro study, reduced proliferation was observed upon small interfering RNA (siRNA)-
mediated ezrin KD in lung cancer cells (Li et al. 2012). 
In conclusion, various potential signaling pathways and most interestingly the TGF-ȕ, IL-6 
and IFN-Ȗ cascade as well as the PDPN downstream signaling via ERM proteins (also 
discussed in chapter 4.4) should be considered while defining the impact of PDPN on 
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cSCC progression. There are still many unanswered question, hence, further 
investigations are required in order to unravel the underlying molecular mechanism of 
PDPN-induced cSCC tumor cell proliferation and invasion. Apart from the potential role of 
the IL-6 and TGF-ȕ signaling as well as ERM proteins, one should keep in mind that other 
pathways or additional interaction partners might contribute to the mechanism as well.  
 
4.8 Conclusion and Future Perspective 
In this dissertation I showed that PDPN acts as a driver of tumorigenesis in differentiated 
cSCC. In vitro and in vivo LOF experiments demonstrated that PDPN induces tumor cell 
proliferation and invasion. Additional future studies are required to define involved 
signaling pathways. 
To tackle this, I suggest generating PDPN mutants in order to evaluate whether the 
interaction of PDPN with its known extracellular partner CLEC-2, the IC binding of the ERM 
proteins or possibly other, yet unknown proteins are essential for tumor cell invasion and 
proliferation. For this purpose, I have initiated experiments, in which specific point 
mutations are introduced into the murine Pdpn gene sequence that inhibit the known 
specific interactions: (i) mutation of the CLEC-2 binding site resulting in the transition of 
Thr34 to Ala34; (ii) change of charged to uncharged amino acids in the IC amino acid 
sequence being responsible for ERM-binding (KK…RNN…Q). In previous studies, the 
same Pdpn mutants were generated and showed a diminished PDPN function. Bianchi 
and colleagues revealed that the mutant PDPN-CLEC-2 binding site resulted in reduced 
CLEC-2 activation in vitro and prolonged bleeding time due to decreased platelet activation 
in vivo (Bianchi et al. 2014). Moreover, Martín-Villar and co-workers mutated the ERM 
binding site and ectopically overexpressed this mutant in MDCK cells, which resulted in 
reduced migratory ability compared to PDPN WT-expressing cells (Martin-Villar et al. 
2006). The generated mutants will be used in different functional in vitro and in vivo 
experiments, as performed in this study and will give insights into interaction partners and 
signaling pathways that contribute to PDPN-induced proliferation and invasion in cSCC.  
Various signaling pathways have already been described that are involved or accompany 
PDPN-driven SCC carcinogenesis. Therefore, I propose to perform a gene expression 
analysis of tumor samples. Depending on the outcome of the Pdpn mutant study, genetic 
profiles of tumors derived from control, Pdpn KO and mutant cSCC cells should be 
examined. This analysis will reveal whether similar or other signaling pathways as 
described are differentially regulated in differentiated cSCC.  
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Altogether, these findings will further contribute to the understanding whether PDPN, its 
interaction partners or IC downstream effectors might represent a promising target for the 
development of a novel cSCC therapy. PDPN is expressed in different health tissue and it 
has been demonstrated that its molecular mass varies between tissues. This implies that 
the post-translational addition of sugar residues might be organ-specific. The development 
of a cancer-specific PDPN antibody that only binds to PDPN, which is expressed by tumor 
cells but not by healthy tissue, indicated that the glycosylation can be modified in a tumor-
specific manner (Kato and Kaneko 2014). Thus, such antibodies might represent a 
possibility to develop chimeric antigen receptor (CAR) T cells, which can specifically target 
tumor cells that express PDPN with an abnormal glycosylation. However, a potential 
drawback might be the differential modification of the sugar residues between individual 
patients, which has not been investigated yet. Notably, in vitro protein expression analysis 
of different cSCC cell lines established from various patient tumor samples implies that the 
glycosylation might vary between individuals as well as primary and metastatic lesions 
(data not shown). Thus, an antibody that targets cancer-specific glycosylation of PDPN 
would not represent the most appropriate therapeutic strategy, since not all tumors might 
display similar glycosylation pattern, which would provoke the development of 
personalized antibody therapy.  
Therefore, the proposed mechanistical study using Pdpn mutants is crucial to define the 
mode of action in PDPN-dependent cSCC progression. If the CLEC-2 mutant phenocopies 
the behavior of Pdpn KO cells, future studies should focus on the interaction of PDPN and 
CLEC-2 in cSCC as well as on the discovery of potential additional PDPN interaction 
partners. Several antibodies were developed that neutralize the PDPN-CLEC-2 interaction 
and subsequent PDPN-mediated platelet aggregation as well as pulmonary metastasis in 
vitro and in vivo approaches (reviewed in Takemoto et al. (2017)). Furthermore, tumor 
cells that are covered by platelets are protected from shear stress and elimination by 
immune cells. However, the validation of developed antibodies strongly depends on 
appropriate model systems that are limited and moreover, the blockage of this interaction 
can cause enhanced bleeding in patients with thrombocytopenia due to chemotherapeutic 
toxicity. Thus, further investigations are still required. If the cytoplasmic tail mimics the 
effect of Pdpn KO cells, the IC signaling via ERM and Rho GTPases might represent 
potential targets. It is important to keep in mind that also other transmembrane proteins 
like CD44, which is commonly upregulated in epithelial cancers, can trigger migration via 
the induction of ERM proteins as well (Hirao et al. 1996, Yonemura et al. 1998, Isacke and 
Yarwood 2002). Since the ERM binding site in CD44 and PDPN differ, the blockage of 
their downstream targets like ERM proteins or Rho GTPases would be recommendable to 
prevent compensatory mechanisms. The small-molecule Quinocarmycin was reported to 
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target radixin and thereby inhibiting its interaction with actin and CD44 (Kahsai et al. 2006). 
However, a previously performed clinical phase I trial in refractory solid malignancies 
demonstrated that this drug is poorly tolerable besides its inability to reach an inhibitory 
effect in vivo tumor growth (Bunnell 2001). Consequently, it was not investigated further in 
phase II studies. Inhibitors blocking Rho GTPases and their effectors are already under 
investigation, however, the biggest challenge is their druggability and inhibitors are still at 
early stages of development (reviewed in Lin and Zheng (2015)).  
In conclusion, the described interventions targeting PDPN or its known extracellular or IC 
partners would rather impair further progression than eradicating the existing tumor. The 
blockage of PDPN-CLEC-2 axis would increase the exposure to tumor-infiltrating immune 
cells, since tumor cell coverage by platelets would be impaired as well as the activation of 
DCs would be diminished, which normally suppress the pro-tumorigenic immune response 
via T cells (Acton et al. 2014). Inhibiting the IC downstream signaling would result in 
reduced tumor cell invasion as cytoskeletal remodeling mediated via ERM or Rho 
GTPases would be impaired. Although these proposed strategies would not eliminate the 
tumor, they would represent a first success, since locally advanced late-stage tumors have 
a poor prognostic outcome (Vinicius de et al. 2011). In order to eradicate cSCC cells, 
signaling pathways need to be identified, which accompany PDPN-expressing tumor cells 
at the invasive front or which are dependent on PDPN expression.
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